<?xml version="1.0" encoding="UTF-8"?>
<questel-patent-document lang="en" date-produced="20180805" produced-by="Questel" schema-version="3.23" file="US06184354B2.xml">
  <bibliographic-data lang="en">
    <publication-reference publ-desc="Granted patent as second publication">
      <document-id>
        <country>US</country>
        <doc-number>06184354</doc-number>
        <kind>B2</kind>
        <date>20010206</date>
      </document-id>
      <document-id data-format="questel">
        <doc-number>US6184354</doc-number>
      </document-id>
    </publication-reference>
    <original-publication-kind>B2</original-publication-kind>
    <application-reference family-id="25406334" extended-family-id="454826">
      <document-id>
        <country>US</country>
        <doc-number>08462794</doc-number>
        <kind>A</kind>
        <date>19950605</date>
      </document-id>
      <document-id data-format="questel">
        <doc-number>1995US-08462794</doc-number>
      </document-id>
      <document-id data-format="questel_Uid">
        <doc-number>466448</doc-number>
      </document-id>
    </application-reference>
    <language-of-filing>en</language-of-filing>
    <language-of-publication>en</language-of-publication>
    <priority-claims>
      <priority-claim kind="national" sequence="1">
        <country>US</country>
        <doc-number>46279495</doc-number>
        <kind>A</kind>
        <date>19950605</date>
        <priority-active-indicator>N</priority-active-indicator>
      </priority-claim>
      <priority-claim data-format="questel" sequence="1">
        <doc-number>1995US-08462794</doc-number>
      </priority-claim>
      <priority-claim kind="national" sequence="2">
        <country>US</country>
        <doc-number>89651292</doc-number>
        <kind>A</kind>
        <date>19920609</date>
        <priority-linkage-type>C</priority-linkage-type>
        <priority-active-indicator>Y</priority-active-indicator>
      </priority-claim>
      <priority-claim data-format="questel" sequence="2">
        <doc-number>1992US-07896512</doc-number>
      </priority-claim>
    </priority-claims>
    <dates-of-public-availability>
      <publication-of-grant-date>
        <date>20010206</date>
      </publication-of-grant-date>
    </dates-of-public-availability>
    <classifications-ipcr>
      <classification-ipcr sequence="1">
        <text>C07K  14/53        20060101A I20051008RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>53</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051008</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="2">
        <text>C12N  15/02        20060101AFI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>02</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="3">
        <text>A61K  38/00        20060101ALI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>A</section>
        <class>61</class>
        <subclass>K</subclass>
        <main-group>38</main-group>
        <subgroup>00</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="4">
        <text>C07K  14/535       20060101ALI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>535</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="5">
        <text>C07K  14/715       20060101A I20051008RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>715</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051008</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="6">
        <text>C12N   1/21        20060101ALI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>1</main-group>
        <subgroup>21</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="7">
        <text>C12N  15/09        20060101ALI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>09</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="8">
        <text>C12N  15/12        20060101A I20060521RMDE</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>12</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>DE</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20060521</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="9">
        <text>C12N  15/27        20060101A I20060521RMEP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>N</subclass>
        <main-group>15</main-group>
        <subgroup>27</subgroup>
        <classification-value>I</classification-value>
        <generating-office>
          <country>EP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20060521</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="10">
        <text>C12P  21/02        20060101ALI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>P</subclass>
        <main-group>21</main-group>
        <subgroup>02</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="11">
        <text>C12R   1/19        20060101ALN20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>C</section>
        <class>12</class>
        <subclass>R</subclass>
        <main-group>1</main-group>
        <subgroup>19</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>N</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
      <classification-ipcr sequence="12">
        <text>G01N  33/566       20060101ALI20051220RMJP</text>
        <ipc-version-indicator>
          <date>20060101</date>
        </ipc-version-indicator>
        <classification-level>A</classification-level>
        <section>G</section>
        <class>01</class>
        <subclass>N</subclass>
        <main-group>33</main-group>
        <subgroup>566</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <generating-office>
          <country>JP</country>
        </generating-office>
        <classification-status>R</classification-status>
        <classification-data-source>M</classification-data-source>
        <action-date>
          <date>20051220</date>
        </action-date>
      </classification-ipcr>
    </classifications-ipcr>
    <classification-national>
      <country>US</country>
      <main-classification>
        <text>530351000</text>
        <class>530</class>
        <subclass>351000</subclass>
      </main-classification>
      <further-classification sequence="1">
        <text>530350000</text>
        <class>530</class>
        <subclass>350000</subclass>
      </further-classification>
    </classification-national>
    <classifications-ecla>
      <classification-ecla sequence="1">
        <text>C07K-014/53</text>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>53</subgroup>
      </classification-ecla>
      <classification-ecla sequence="2">
        <text>C07K-014/715D</text>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>014</main-group>
        <subgroup>715D</subgroup>
      </classification-ecla>
    </classifications-ecla>
    <patent-classifications>
      <patent-classification sequence="1">
        <classification-scheme office="EP" scheme="CPC">
          <date>20130101</date>
        </classification-scheme>
        <classification-symbol>C07K-014/53</classification-symbol>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>53</subgroup>
        <symbol-position>F</symbol-position>
        <classification-value>I</classification-value>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
        <action-date>
          <date>20130101</date>
        </action-date>
      </patent-classification>
      <patent-classification sequence="2">
        <classification-scheme office="EP" scheme="CPC">
          <date>20130101</date>
        </classification-scheme>
        <classification-symbol>C07K-014/7153</classification-symbol>
        <section>C</section>
        <class>07</class>
        <subclass>K</subclass>
        <main-group>14</main-group>
        <subgroup>7153</subgroup>
        <symbol-position>L</symbol-position>
        <classification-value>I</classification-value>
        <classification-status>B</classification-status>
        <classification-data-source>H</classification-data-source>
        <action-date>
          <date>20130101</date>
        </action-date>
      </patent-classification>
    </patent-classifications>
    <number-of-claims>3</number-of-claims>
    <exemplary-claim>1</exemplary-claim>
    <figures>
      <number-of-drawing-sheets>8</number-of-drawing-sheets>
      <number-of-figures>7</number-of-figures>
      <image-key data-format="questel">US6184354</image-key>
    </figures>
    <invention-title format="original" lang="en" id="title_en">Soluble extracellular domain of human M-CSF receptor</invention-title>
    <references-cited>
      <citation srep-phase="examiner">
        <patcit num="1">
          <text>SMITH CRAIG A, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>5589456</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US5589456</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="2">
          <text>DAVIS FRANK F, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4179337</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4179337</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="3">
          <text>ERLICH HENRY A</text>
          <document-id>
            <country>US</country>
            <doc-number>4582788</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4582788</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="4">
          <text>KUNG HSIANG-FU, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4672108</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4672108</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="5">
          <text>MULLIS KARY B, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4683195</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4683195</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="6">
          <text>MULLIS KARY B</text>
          <document-id>
            <country>US</country>
            <doc-number>4683202</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4683202</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="7">
          <text>FUJITA SHOZO, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4755363</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4755363</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="8">
          <text>CARTER DANIEL C</text>
          <document-id>
            <country>US</country>
            <doc-number>4833233</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4833233</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="9">
          <text>KASWASAKI ERNEST S, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4847201</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4847201</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="10">
          <text>LADNER ROBERT C</text>
          <document-id>
            <country>US</country>
            <doc-number>4881175</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4881175</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="11">
          <text>PANTOLIANO MICHAEL W, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4908773</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4908773</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="12">
          <text>HALENBECK ROBERT, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4929700</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4929700</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="13">
          <text>LADNER ROBERT C, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4946778</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4946778</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="14">
          <text>CLARK JOHN I, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>4966911</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US4966911</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="15">
          <text>DEELEY MICHAEL, et al</text>
          <document-id>
            <country>US</country>
            <doc-number>5032676</doc-number>
            <kind>A</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>US5032676</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="16">
          <text>CETUS CORP</text>
          <document-id>
            <country>EP</country>
            <doc-number>0272779</doc-number>
            <kind>A2</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-272779</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="17">
          <text>CHUGAI PHARMACEUTICAL CO LTD</text>
          <document-id>
            <country>EP</country>
            <doc-number>0344796</doc-number>
            <kind>A2</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-344796</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="18">
          <text>SCHERING CORP</text>
          <document-id>
            <country>EP</country>
            <doc-number>0402070</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>EP-402070</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="19">
          <text>CETUS CORP</text>
          <document-id>
            <country>WO</country>
            <doc-number>8808003</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>WO8808003</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="20">
          <text>NOVO NORDISK AS</text>
          <document-id>
            <country>WO</country>
            <doc-number>9109943</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>WO9109943</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="applicant">
        <patcit num="21">
          <text>GENENTECH INC</text>
          <document-id>
            <country>WO</country>
            <doc-number>9221029</doc-number>
            <kind>A1</kind>
          </document-id>
          <document-id data-format="questel">
            <doc-number>WO9221029</doc-number>
          </document-id>
        </patcit>
      </citation>
      <citation srep-phase="examiner">
        <nplcit num="1">
          <text>Duan et al. J. Biol. Chem. 266:413-418 (1990).</text>
        </nplcit>
      </citation>
      <citation srep-phase="examiner">
        <nplcit num="2">
          <text>Bowie et al. (1990) Science 247:1307-1310.</text>
        </nplcit>
      </citation>
      <citation srep-phase="examiner">
        <nplcit num="3">
          <text>Himmler et al. (1990) DNA and Cell Biology 9:705-715, 1990.</text>
        </nplcit>
      </citation>
      <citation srep-phase="examiner">
        <nplcit num="4">
          <text>Raines et al. (1991) Proc. Natl. Acad. Sci. 88:8203-8207, Sep. 1991.</text>
        </nplcit>
      </citation>
      <citation srep-phase="examiner">
        <nplcit num="5">
          <text>Callard et al. (1994) The Cytokine Factbook, Academic Press, pp. 3 and 174-178.</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="6">
          <text>Bricogne, G., "Methods and Programs for Direct-Space Exploitation of Geometric Redundancies," Acta Cryst., 32:832-847 (1976).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="7">
          <text>Burnette, W.N., ""Western Blotting":Electrophoretic Transfer of Proteins from Sodium Dodecyl Sulfate-Polyacrylamide Gels to Unmodified Nitrocellulose and Radiographic Detection with Antibody and Radioiodinated Protein A," Anal. Biochem., 112:195-203 (1981).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="8">
          <text>Cerretti et al., "Human Macrophage-Colony Stimulating Factor: Alternative RNA and Protein Processing From a Single Gene," Molecular Immunology, 25(8):761-770, (1988).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="9">
          <text>Coussens et al., "Structural Alterations of Viral Homologue of Receptor Proto-Oncogene fms at Carboxyl Terminus," Nature, 320:277-280 (1986).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="10">
          <text>Cox, J.M., "Mathematical Methods Used in the Comparison of the Quanternary Structures," (Appendix) J. Mol. Biol., 28:151-156 (1967).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="11">
          <text>Creighton, T.E., Proteins: Structural and Molecular Properties, W.H. Freeman and Co., San Francisco, pp. 79-86 (1983).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="12">
          <text>Cunningham et al., "Dimerization of the Extracellular Domain of the Human Growth Hormone Receptor by a Single Hormone Molecule," Science, 254:821-825 (Nov. 8, 1991).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="13">
          <text>Fetrow and Bryant, "New Programs for Protein Tertiary Structure Prediction," Bio/Technology, 11:479-484 (Apr. 11, 1993).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="14">
          <text>Gillam et al., "Site-Specific Mutagenesis Using Synthetic Oligodeoxyribonucleotide Primers: I. Optimum Conditions and Minimum Oligodeoxyribonucleotide Length," Gene, 8:81-97 (1979).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="15">
          <text>Halenbeck et al., "Renaturation and Purification of Biologically Active Recombinant Human Macrophage Colony-Stimulating Factor Expressed in E. coli," Bio/Technology, 7:710-715 (Jul., 1989).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="16">
          <text>Home et al., "What is Light," New Scientist, 2:30-33 (Nov. 2, 1991).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="17">
          <text>Luria et al., "Hybridization Between Escherichia coli and Shigella," J. Bact., 74:461-476 (1957).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="18">
          <text>Jancarik et al., "Sparse Matrix Sampling: A Screening Method For Crystallization of Proteins," J. Appl. Cryst., 24:409-411 (1991).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="19">
          <text>Jones, T.A., "Interactive Computer Graphics: FRODO," Methods Enzymol., 115:157-171 (1985).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="20">
          <text>Kabsch et al., "Dictionary of Protein Secondary Structure: Pattern Recognition of Hydrogen-Bonded and Geometrical Features," Biopolymers, 22:2577-2637 (1983).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="21">
          <text>Kawasaki et al., "Molecular Cloning of a Complimentary DNA Encoding Human Macrophage-Specific Colony-Stimulating Factor (CSF-1)," Science, 230:291-296, (1985).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="22">
          <text>Ladner et al., "Human CSF-1: Gene Structure and Alternative Splicing of mRNA Precursors," EMBO J., 6:2693-2698, (1987).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="23">
          <text>Laemmli, U.K., "Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4," Nature (Canada), 227:680-685 (Aug. 15, 1970).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="24">
          <text>LaLonde et al., "Crystallization and Preliminary X-Ray Studies of Recombinant Human Granulocyte-Macrophage Colony Stimulating Factor," J. Mol. Biol., 205(4):783-785 (1989).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="25">
          <text>Luckov et al., "Trends in the Development of Baculovirus Expression Vectors," Bio/Technology, 6:47-55 (Jan., 1988).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="26">
          <text>McPherson, A., Preparation and Analysis of Protein Crystals, A Wiley-Interscience Publication, John Wiley &amp; Sons, New York, pp. 102-104 (1982).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="27">
          <text>McPherson, Jr., "Crystallization of Proteins From Polyethylene Glycol," J. Biol. Chem., 251(20):6300-6303 (Oct. 25, 1976).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="28">
          <text>Metcalf, "Studies on Colony Formation In Vitro by Mouse Bone Marrow Cells," J. Cell. Physiol., 76(1):89-99 (Aug., 1970).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="29">
          <text>Miles, E.W., "Modification of Histidyl Residues in Proteins by Diethylpyrocarbonate," Meth Enzymol., 47:431-442 (1977).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="30">
          <text>Mullis et al., "Specific Synthesis of DNA in vitro via a Polymerase-Catalyzed Chain Reaction," Meth. Enzymol., 155:335-350 (1987).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="31">
          <text>Mullis, K.B., "Specific Enzymatic Amplification of DNA In Vitro: The Polymerase Chain Reaction," Cold Spring Harbor Symp. on Quant. Biol. 51:263-273 (1986).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="32">
          <text>Ollis and White, "Protein Crystallization," Guide to Protein Purification, Methods in Enzymology, vol. 182, Deutscher (ed.), Academic Press, Inc., Harcourt Brace Jovanovich, Publishers, San Diego, CA, pp. 646-659 (1991).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="33">
          <text>Pandit et al., "Three-Dimensional Structure of Dimeric Human Recombinant Macrophage Colony-Stimulating Factor," Science, 258:1358-1362 (Nov. 20, 1992).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="34">
          <text>Ralph et al., "Molecular and Biological Properties of Human Macrophage Growth Factor, CSF-1," Cold Spring Harbor Symposia on Quantitative Biology, LI:679-683 (1986).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="35">
          <text>Ralph et al., "The Molecular and Biological Properties of the Human and Murine Members of the CSF-1 Family" in Molecular Basis of Lymphokine Action, Humana Press, Inc., pp. 295-311 (1987).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="36">
          <text>Ralph et al., "Inducible Production of Human Macrophage Growth Factor, CSF-1," Blood, 68:633-639 (1986).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="37">
          <text>Roberts et al., "Generation of an Antibody With Enhanced Affinity and Specificity for Its Antigen by Protein Engineering," Nature, 328:731-734 (Aug. 20, 1987).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="38">
          <text>Saiki et al., "A Novel Method for the Detection of Polymorphic Restriction Sites By Cleavage of Oligonucleotide Probes: Application to Sickle-Cell Anemia," Bio/Technology, 3:1008-10012 (Nov., 1985).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="39">
          <text>Scopes, R.K., "Crystallization of Proteins," Protein Purification: Principles and Practice, Chapter 10 (10.3), Second Edition, Springer-Verlag, pp. 296-321 (1982).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="40">
          <text>Shadle et al., Human Macrophage Colony-Stimulating Factor Heterogeneity Results From Alternative mRNA Splicing, Deferential Glycosylation, and Proteolytic Processing, J. Cellular Biochem, 40:91-107 (1989).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="41">
          <text>Sporn and Roberts, (eds.), "Peptide Growth Factors and Their Receptors," Handbook of Experimental Pharmacology, vol. 1; vol. 95/1, Springer-Verlag, pp. 667-698 (1990).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="42">
          <text>Stanley et al., "Standardized Bioassay For Bone Marrow Colony Stimulating Factor In Human Urine: Levels in Normal Man," J. Lab. Clin. Med., 79:657-668 (1972).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="43">
          <text>Van Holde, K.E., "X-Ray Diffraction," Physical Biochemistry, Chapter 11, Prentice Hall, N.J. pp. 221-239 (1971).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="44">
          <text>Wang, B.C., "Resolution of Phase Ambiguity in Macromolecular Crystallography," Methods Enzymol., 115:90-112 (1985).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="45">
          <text>Ward et al., "Structure of Deoxyhemoglobin A Crystals Grown from Polyethylene Glycol Solutions," J. Mol. Biol., 98:161-177 (1975).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="46">
          <text>Weber, P.C., "Physical Principals of Protein Crystallization," Advances in Protein Chemistry, 41:1-36 (1991).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="47">
          <text>Yeung et al., "Purification of the Colony Stimulating Factor 1 Receptor and Demonstration of its Tyrosine Kinase Activity," Proc. Nat'l Acad. Sci., USA, 84:1268-1271 (Mar., 1987).</text>
        </nplcit>
      </citation>
      <citation srep-phase="applicant">
        <nplcit num="48">
          <text>BrÃ«nger, A.T., "Crystallographic Refinement by Stimulated Annealing," J. Mol. Biol., 203:803-816 (1988).</text>
        </nplcit>
      </citation>
    </references-cited>
    <related-documents>
      <related-publication>
        <document-id>
          <country>US</country>
          <doc-number>89651292</doc-number>
          <kind>A</kind>
          <date>19920609</date>
        </document-id>
      </related-publication>
      <continuation>
        <relation>
          <parent-doc>
            <document-id>
              <country>US</country>
              <doc-number>5866114</doc-number>
              <kind>A</kind>
            </document-id>
          </parent-doc>
        </relation>
        <relation>
          <parent-doc>
            <document-id>
              <country>US</country>
              <doc-number>08/351292</doc-number>
            </document-id>
          </parent-doc>
        </relation>
      </continuation>
      <previous-publication>
        <relation>
          <parent-doc>
            <document-id>
              <country>WO</country>
              <doc-number>PCT/US93/05548</doc-number>
              <date>19930609</date>
            </document-id>
          </parent-doc>
        </relation>
      </previous-publication>
    </related-documents>
    <parties>
      <applicants>
        <applicant data-format="original" app-type="applicant" sequence="1">
          <addressbook lang="en">
            <orgname>Chiron Corporation</orgname>
            <address>
              <address-1>Emeryville, CA, US</address-1>
              <city>Emeryville</city>
              <state>CA</state>
              <country>US</country>
            </address>
          </addressbook>
          <nationality>
            <country>US</country>
          </nationality>
        </applicant>
        <applicant data-format="questel" app-type="applicant" sequence="2">
          <addressbook lang="en">
            <orgname>CHIRON</orgname>
          </addressbook>
          <nationality>
            <country>US</country>
          </nationality>
        </applicant>
      </applicants>
      <inventors>
        <inventor data-format="original" sequence="1">
          <addressbook lang="en">
            <name>Koths, Kirston</name>
            <address>
              <address-1>El Cerrito, CA, US</address-1>
              <city>El Cerrito</city>
              <state>CA</state>
              <country>US</country>
            </address>
          </addressbook>
          <nationality>
            <country>US</country>
          </nationality>
        </inventor>
        <inventor data-format="original" sequence="2">
          <addressbook lang="en">
            <name>Taylor, Eric</name>
            <address>
              <address-1>Oakland, CA, US</address-1>
              <city>Oakland</city>
              <state>CA</state>
              <country>US</country>
            </address>
          </addressbook>
          <nationality>
            <country>US</country>
          </nationality>
        </inventor>
      </inventors>
      <agents>
        <agent sequence="1" rep-type="agent">
          <addressbook lang="en">
            <name>Pochopien, Donald J.</name>
          </addressbook>
        </agent>
        <agent sequence="2" rep-type="agent">
          <addressbook lang="en">
            <name>Morley, Kimberlin L.</name>
          </addressbook>
        </agent>
        <agent sequence="3" rep-type="agent">
          <addressbook lang="en">
            <name>Blackburn, Robert P.</name>
          </addressbook>
        </agent>
      </agents>
    </parties>
    <examiners>
      <primary-examiner>
        <name>Pak, Michael</name>
      </primary-examiner>
    </examiners>
    <lgst-data>
      <lgst-status>EXPIRED</lgst-status>
    </lgst-data>
  </bibliographic-data>
  <abstract format="original" lang="en" id="abstr_en">
    <p id="P-EN-00001" num="00001">
      <br/>
      The present invention is directed to methods for crystallizing macrophage colony stimulating factor.
      <br/>
      The present invention is also directed to methods for designing and producing M-CSF agonists and antagonists using information derived from the crystallographic structure of M-CSF.
      <br/>
      The invention is also directed to methods for screening M-CSF agonists and antagonists.
      <br/>
      In addition, the present invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
    </p>
  </abstract>
  <description format="original" lang="en" id="desc_en">
    <p num="1">
      This is a continuation of U.S. application Ser.
      <br/>
      No. 08/351,292 filed May 25, 1995, now U.S. Pat. No. 5,866,114; which is the U.S. national phase of international application PCT/US93/05548 filed on Jun. 9, 1993; which is a continuation-in-part of U.S. application Ser.
      <br/>
      No. 07/896,512 filed Jun. 9, 1992, now abandoned.
    </p>
    <p num="2">
      Work described herein was funded with Government support.
      <br/>
      The Government has certain rights in inventions arising as part of that work.
    </p>
    <heading>FIELD OF THE INVENTION</heading>
    <p num="3">The present invention relates in general to crystalline compositions of macrophage colony stimulating factor "M-CSF" and in particular to methods for the use of structural information (including X-ray diffraction patterns) of crystalline M-CSF for agonist and antagonist production, as well as assays for detection of same.</p>
    <heading>BACKGROUND OF THE INVENTION</heading>
    <p num="4">
      Monocyte-macrophage colony-stimulating factor is produced by a variety of cells, including macrophages, endothelial cells and fibroblasts (see, Ralph et al., "The Molecular and Biological Properties of the Human and Murine Members of the CSF-1 Family" in Molecular Basis of Lymphokine Action, Humana Press, Inc., (1987), which is incorporated herein by reference). M-CSF is composed of two "monomer" polypeptides, which form a biologically active dimeric M-CSF protein (hereinafter referred to as "M-CSF dimer"). M-CSF belongs to a group of biological agonists that promote the production of blood cells.
      <br/>
      Specifically, it acts as a growth and differentiation factor for bone marrow progenitor cells of the mononuclear phagocyte lineage.
      <br/>
      Further, M-CSF stimulates the proliferation and function of mature macrophages via specific receptors on responding cells.
      <br/>
      In clinical trials M-CSF has shown promise as a pharmaceutical agent in the correction of blood cell deficiencies arising as a side-effect of chemotherapy or radiation therapy for cancer and may be beneficial in treating fungal infections associated with bone marrow transplants. M-CSF may also play significant biological roles in pregnancy, uveitis, and atherosclerosis.
      <br/>
      Development of M-CSF agonists or antagonists may prove to be of value in modifying the biological events involved in these conditions.
    </p>
    <p num="5">
      M-CSF exists in at least three mature forms: short (M-CSF ALPHA ), intermediate (M-CSF GAMMA ), and long (M-CSF BETA ).
      <br/>
      Mature M-CSF is defined as including polypeptide sequences contained within secreted M-CSF following amino terminus processing to remove leader sequences and carboxyl terminus processing to remove domains including a putative transmembrane region.
      <br/>
      The variations in the three mature forms are due to alternative mRNA splicing (see, Cerretti et al.
      <br/>
      Molecular Immunology, 25:761 (1988)).
      <br/>
      The three forms of M-CSF are translated from different mRNA precursors, which encode polypeptide monomers of 256 to 554 amino acids, having a 32 amino acid signal sequence at the amino terminal and a putative transmembrane region of approximately 23 amino acids near the carboxyl terminal.
      <br/>
      The precursor peptides are subsequently processed by amino terminal and carboxyl terminal proteolytic cleavages to release mature M-CSF.
      <br/>
      Residues 1-149 of all three mature forms of M-CSF are identical and are believed to contain sequences essential for biological activity of M-CSF.
      <br/>
      In vivo M-CSF monomers are dimerized via disulfide-linkage and are glycosylated.
      <br/>
      Some, if not all, forms of M-CSF can be recovered in membrane-associated form.
      <br/>
      Such membrane-bound M-CSF may be cleaved to release secreted M-CSF.
      <br/>
      Membrane associated M-CSF is believed to have biological activity similar to M-CSF, but may have other activities including cell--cell association or activation.
    </p>
    <p num="6">
      Polypeptides, including the M-CSFs, have a three-dimensional structure determined by the primary amino acid sequence and the environment surrounding the polypeptide.
      <br/>
      This three-dimensional structure establishes the polypeptide's activity, stability, binding affinity, binding specificity, and other biochemical attributes.
      <br/>
      Thus, a knowledge of a protein's three-dimensional structure can provide much guidance in designing agents that mimic, inhibit, or improve its biological activity in soluble or membrane bound forms.
    </p>
    <p num="7">
      The three-dimensional structure of a polypeptide may be determined in a number of ways.
      <br/>
      Many of the most precise methods employ X-ray crystallography (for a general review, see, Van Holde, Physical Biochemistry, Prentice-Hall, N.J. pp. 221-239, (1971), which is incorporated herein by reference).
      <br/>
      This technique relies on the ability of crystalline lattices to diffract X-rays or other forms of radiation.
      <br/>
      Diffraction experiments suitable for determining the three dimensional structure of macromolecules typically require high-quality crystals.
      <br/>
      Unfortunately, such crystals have been unavailable for M-CSF as well as many other proteins of interest.
      <br/>
      Thus, high-quality, diffracting crystals of M-CSF would assist the determination of its three-dimensional structure.
    </p>
    <p num="8">
      Various methods for preparing crystalline proteins and polypeptides are known in the art (see, for example, McPherson, et al. "Preparation and Analysis of Protein Crystals", A. McPherson, Robert E. Krieger Publishing Company, Malabar, Fla. (1989); Weber, Advances in Protein Chemistry 41:1-36 (1991); U.S. Pat. No. 4,672,108; and U.S. Pat. No. 4,833,233; all of which are incorporated herein by reference for all purposes).
      <br/>
      Although there are multiple approaches to crystallizing polypeptides, no single set of conditions provides a reasonable expectation of success, especially when the crystals must be suitable for X-ray diffraction studies.
      <br/>
      Thus, in spite of significant research, many proteins remain uncrystallized.
    </p>
    <p num="9">
      In addition to providing structural information, crystalline polypeptides provide other advantages.
      <br/>
      For example, the crystallization process itself further purifies the polypeptide, and satisfies one of the classical criteria for homogeneity.
      <br/>
      In fact, crystallization frequently provides unparalleled purification quality, removing impurities that are not removed by other purification methods such as HPLC, dialysis, conventional column chromatography, etc.
      <br/>
      Moreover, crystalline polypeptides are often stable at ambient temperatures and free of protease contamination and other degradation associated with solution storage.
      <br/>
      Crystalline polypeptides may also be useful as pharmaceutical preparations.
      <br/>
      Finally, crystallization techniques in general are largely free of problems such as denaturation associated with other stabilization methods (e.g. lyophilization).
      <br/>
      Thus, there exists a significant need for preparing M-CSF compositions in crystalline form and determining their three-dimensional structure.
      <br/>
      The present invention fulfills this and other needs.
      <br/>
      Once crystallization has been accomplished, crystallographic data provides useful structural information which may assist the design of peptides that may serve as agonists or antagonists.
      <br/>
      In addition, the crystal structure provides information useful to map, the receptor binding domain which could then be mimicked by a small non-peptide molecule which may serve as an antagonist or agonist.
    </p>
    <heading>SUMMARY OF THE INVENTION</heading>
    <p num="10">
      The present invention provides crystalline forms of M-CSF dimers.
      <br/>
      Preferably, the dimers are formed from polypeptides containing between 146 to 162 amino acids residues at or near the N-terminus of mature M-CSF (e.g. glu1 glu2 val3 . . . ).
      <br/>
      In a specific embodiment, the polypeptide includes residues 4 to 158 of mature M-CSF ALPHA  polypeptide, preferably in the non-glycosylated form.
    </p>
    <p num="11">
      Another aspect of the invention provides a method of crystallizing an M-CSF.
      <br/>
      A preferred crystallization method according to the present invention includes the following steps: mixing a preselected, substantially pure M-CSF dimer and a precipitant to form an M-CSF mixture; precipitating crystalline M-CSF from the mixture; and isolating the M-CSF in crystalline form.
      <br/>
      In some specific embodiments, the precipitant contains polyethylene glycol.
      <br/>
      Other components such as ammonium sulfate and/or other ionic compounds may be added to the solution.
      <br/>
      It has been found by x-ray crystallography that M-CSF produced by the method of the present invention can crystallize into the P21 21 21 space groups for example.
    </p>
    <p num="12">
      Variations of the crystallization method are also provided.
      <br/>
      For example, the step of precipitating crystals from the M-CSF mixture may involve equilibrating the M-CSF mixture with a second mixture.
      <br/>
      The second mixture is typically a solution that consists of a higher concentration of precipitant than the first M-CSF mixture.
      <br/>
      The step of equilibrating preferably consists of applying the M-CSF mixture to a surface and allowing the applied M-CSF mixture to come into equilibrium with a reservoir of the second mixture.
      <br/>
      In other embodiments, the step of precipitating M-CSF crystals is initiated by seeding the M-CSF mixture with seed crystals or altering the temperature of the M-CSF mixture.
      <br/>
      Another aspect of the invention involves identifying compounds that have structures that mimic a receptor binding region of the three-dimensional structure of M-CSF to varying degrees and can in many instances function as M-CSF agonists or antagonists.
      <br/>
      Compounds that interact with the receptor-binding region of M-CSF may be antagonists.
      <br/>
      The three-dimensional alpha-carbon coordinates of a truncated M-CSF dimer is presented in Appendix 1.
      <br/>
      In one embodiment of the present invention, the three-dimensional structure of M-CSF is obtained by first crystallizing an M-CSF dimer (having M-CSF receptor-binding residues) to form at least one M-CSF crystal.
      <br/>
      Next, a source of radiation is used for irradiating an M-CSF crystal to obtain a diffraction pattern of the M-CSF crystal.
      <br/>
      Finally, a three-dimensional structure of M-CSF is obtained from the diffraction pattern.
      <br/>
      In most embodiments, the three-dimensional structure includes an M-CSF receptor-binding region.
    </p>
    <p num="13">
      The present invention is also directed to a method for selecting, candidate amino acid substitutions in a protein, based on structural information, and more particularly M-CSF, comprising determining the three-dimensional structure of M-CSF by the methods of the present invention; followed by determining the solvent accessible amino acid residues of the protein, determining which residues are not involved in dimer formation.
      <br/>
      Applying these criteria, amino acids in M-CSF which are solvent accessible and which are not involved in dimer formation are selected for substitution with non-conservative amino acids.
      <br/>
      Since M-CSF BETA  has intrachain disulfide bonds involving cysteines 157 and/or 159, we believe the C-terminal region of M-CSF extends from the "rear" of the structure we have solved, providing a variable-length "tether" for membrane-bound forms of M-CSF.
      <br/>
      Thus, the "front" or receptor-binding region of M-CSF is on the opposite side of the molecules, consisting of solvent-accessible residues in or near helices A, C, and D, including residues from about 6 to 26, 71 to 90, and 110 to 130, respectively, of native M-CSF.
      <br/>
      Preferred amino acids for substitution and preferred substituting amino acids include but are not limited to: H15 --&gt; A or L; Q79 --&gt; A or D; R86 --&gt; E or D; E115 --&gt; A; E41 --&gt; K or R; K93 --&gt; A or E; D99 --&gt; K or R; L55 --&gt; Q or N; S18 --&gt; A or K; Q20 --&gt; A or D; 175 --&gt; K or E; V78 --&gt; K or R; L85 --&gt; E or N; D69 --&gt; K or R; N70 --&gt; A or E: H9 --&gt; A or D; N63 --&gt; K or R; and T34 --&gt; Q or K. Most preferred are those substitutions give rise to novel M-CSF agonists and M-CSF antagonists.
      <br/>
      Additionally, the present invention is also directed to a method for producing antagonists and agonists by substituting at least one and preferably fewer than 5 solvent accessible residues per M-CSF monomer.
    </p>
    <p num="14">
      The invention is also directed to heterodimeric M-CSF in which only one subunit contains substituted solvent accessible amino acids involved in signal transduction and to heterodimeric M-CSF in which each subunit contains different substituted solvent accessible amino acids involved in signal transduction.
      <br/>
      The present invention is also directed to M-CSF having amino acid substitutions which do not impair binding to the M-CSF receptor.
      <br/>
      Screening for agonists and antagonists is then accomplished using bioassays and receptor binding assays using methods well known in the art, including those described in the Examples below.
    </p>
    <p num="15">
      In addition the invention is directed to an isolated, purified, soluble and functional M-CSF receptor.
      <br/>
      The present invention is also directed to a method for screening M-CSF agonists and antagonists using a soluble M-CSF receptor.
    </p>
    <p num="16">A further understanding of the present invention can be obtained by reference to the drawings and discussion of specific embodiments.</p>
    <heading>BRIEF DESCRIPTION OF THE FIGURES</heading>
    <p num="17">
      FIG. 1 is a section of a diffraction pattern of an M-CSF ALPHA  crystal prepared according to the present invention;
      <br/>
      FIG. 2 is a topology diagram showing the disulfide bonds in truncated dimeric M-CSF;
      <br/>
      FIG. 3 is a stereodiagram of the C-alpha backbone with every tenth residue labelled and with the non-crystallographic symmetry axis indicated by a dotted line;
      <br/>
      FIGS. 4A and 4B present two views of a ribbon diagram highlighting the secondary structural elements of M-CSF. The cysteine residues have been represented by a ball-and-stick model and the non-crystallographic symmetry axis is indicated by a dotted line;
      <br/>
      FIGS. 5A-5C illustrate size-exclusion HPLC analysis of the N DELTA 3C DELTA 158 M-CSF short clone homodimer (158) (FIG. 5A), N DELTA 3C DELTA 221 C157S, C159S long clone homodimer (221F) (FIG. 5B), and the short clone/long clone heterodimer (158/221F) (FIG. 5C) and their corresponding biological activities;
      <br/>
      FIGS. 6A-6C illustrates size exclusion HPLC(A) and both non-reduced (B) and reduced (C) SDS-PAGE analysis of the preparative purification of M-CSF; more particularly, FIG. 6A graphically illustrates the separation on Phenyl-HPLC size exclusion chromatography of the three species of M-CSF dimers of FIGS. 5A-5C, i.e., the 158 homodimer, the 221F homodimer and the 158/221F heterodimer, and indicates that the three absorbance peaks at 280 nm (solid line) correlate with M-CSF activity in U/ml * 10-6 (dotted line); FIG. 6B illustrates SDS-PAGE analysis under non-reducing conditions of the preparative purification of the 158/221F heterodimer (intermediate molecular weight species) relative to the 158 homodimer (lower molecular weight species) and the 221F homodimer (highest molecular weight species); FIG. 6C illustrates SDS-PAGE analysis under reducing conditions of the preparative purification of the 158/221F heterodimer (middle lanes) relative to the 158 homodimer (left lanes) and the 221F homodimer (right lanes); and
      <br/>
      FIG. 7 illustrates the competitive binding of M-CSF and M-CSF muteins to NFS60 cell M-CSF receptors. In FIG. 7, competitive binding curves are shown for M-CSF ALPHA  N DELTA 3C DELTA 158 (closed circles), M-CSF ALPHA  N DELTA 3C DELTA 158 H9A, H15A/M-CSF BETA  N DELTA 3C DELTA 221 C157S, C159S heterodimer (closed squares), dimeric Q20A, V78KF mutein (open circles) and dimeric H9A, H15A mutein (open squares).
    </p>
    <heading>DESCRIPTION OF THE PREFERRED EMBODIMENTS DEFINITIONS</heading>
    <p num="18">
      As used herein "M-CSF polypeptide" refers to a human polypeptide having substantially the same amino acid sequence as the mature human M-CSF ALPHA , M-CSF BETA , or M-CSF GAMMA  polypeptides described in Kawasaki et al., Science 230:291 (1985), Cerretti et al., Molecular Immunology, 25:761 (1988), or Ladner et al., EMBO Journal 6:2693 (1987), each of which are incorporated herein by reference.
      <br/>
      Such terminology reflects the understanding that the three mature M-CSFs have different amino acid sequences, as described above.
    </p>
    <p num="19">
      Certain modifications to the primary sequence of M-CSF can be made by deletion, addition, or alteration of the amino acids encoded by the DNA sequence without destroying the desired structure (e.g., the receptor binding ability of M-CSF) in accordance with well-known recombinant DNA techniques.
      <br/>
      Further, a skilled artisan will appreciate that individual amino acids may be substituted or modified by oxidation, reduction or other derivitization, and the polypeptide may be cleaved to obtain fragments that retain the active binding site and structural information.
      <br/>
      Such substitutions and alterations result in polypeptides having an amino acid sequence which falls within the definition of polypeptide "having substantially the same amino acid sequence as the mature M-CSF ALPHA , M-CSF BETA , and M-CSF GAMMA  polypeptides."
    </p>
    <p num="20">
      For purposes of crystallization, preferred lengths of the M-CSF ALPHA ,  BETA  or  GAMMA  monomers are between about 145 and 180 amino acids (counting from the mature amino terminus), and more preferably between about 145 and 162 amino acids long.
      <br/>
      A specific monomer that may be present in a crystallizable dimer is M-CSF ALPHA  and is N DELTA 3 M-CSF ALPHA  C DELTA 158 (3 amino acids are deleted from the amino terminus and the total length is 155 amino acids).
      <br/>
      All lengths are inclusive.
      <br/>
      As used herein the term "M-CSF ALPHA  (4-158)" denotes an M-CSF having amino acid residues 4 to 158 of the mature, processed M-CSF ALPHA  polypeptide.
      <br/>
      Other nomenclature designations for C-terminal and N-terminal truncations of native M-CSF are set forth in U.S. Pat. No. 4,929,700 which is incorporated herein by reference.
    </p>
    <p num="21">
      Crystallizable glycosylation variants of the M-CSF polypeptides are included within the scope of this invention.
      <br/>
      These variants include polypeptides; completely lacking in glycosylation and variants having at least one fewer glycosylated site than the mature forms, as well as variants in which the glycosylation pattern has been changed from the native forms.
      <br/>
      Also included are deglycosylated and unglycosylated amino acid sequence variants, as well as deglycosylated and unglycosylated M-CSF subunits having the mature amino acid sequence (see, U.S. Pat. No. 5,032,626).
    </p>
    <p num="22">
      "M-CSF" dimer refers to two M-CSF polypeptide monomers that have dimerized. M-CSF dimers may include two identical polypeptide monomers (homodimers) or two different polypeptide monomers (heterodimers such as an M-CSF ALPHA -M-CSF BETA  dimer, an M-CSF long clone and short clone dimer). M-CSF monomers may be converted to M-CSF dimers in vitro as described in U.S. Pat. No. 4,929,700, which is incorporated herein by reference.
      <br/>
      Recombinantly expressed M-CSFs may also be variably glycosylated as they exist in vivo, partially glycosylated, or completely lacking in glycosylation (unglycosylated).
      <br/>
      Glycosylated M-CSFs may be produced in vivo with carbohydrate chains which may later be enzymatically deglycosylated in vitro.
    </p>
    <p num="23">
      Biologically active M-CSF exhibits a spectrum of activity understood in the art.
      <br/>
      For instance, M-CSF stimulates the proliferation and function of mature macrophages via specific receptors on responding cells.
      <br/>
      Further, M-CSF acts as a mononuclear phagocyte progenitor growth factor.
      <br/>
      The standard in vitro colony stimulating assay of Metcalf, J. Cell Physiol. 76:89 (1970) (which is incorporated herein by reference) results primarily in the formation of macrophage colonies when M-CSF is applied to stem cells.
      <br/>
      Other biological assays are based on M-CSF induced proliferation of M-CSF dependent cells such as the NFS-60 cell line.
      <br/>
      As used herein "M-CSF having biological activity" refers to M-CSF, including fragments and sequence variants thereof as described herein; that exhibit an art-recognized spectrum of activity with respect to biological systems.
      <br/>
      Such M-CSF having biological activity will typically have certain structural attributes in common with those of the mature M-CSF forms such as receptor binding site tertiary structure.
    </p>
    <p num="24">
      Agonists are substances that exhibit greater activity per se than the native ligand while antagonists are substances that suppress, inhibit, or interfere with the biological activity of a native ligand.
      <br/>
      Agonists and antagonists may be produced by the methods of the present invention for use in the treatment of diseases in which M-CSF has been implicated either as a potential treatment (e.g., for treating blood cell deficiencies arising as a side effect of chemotherapy treating fungal infection associated with bone marrow transplants and others) or as having a role in the pathogenesis of the disease (e.g., ovarian cancer, uveitis, atherosclerosis).
    </p>
    <p num="25">Crystallization of M-CSF species in accordance with the present invention includes four general steps: expression, purification, crystallization and isolation.</p>
    <p num="26">Expression of Recombinant M-CSF</p>
    <p num="27">
      M-CSF crystallization requires an abundant source of M-CSF that may be isolated in a relatively homogeneous form.
      <br/>
      A variety of expression systems and hosts are suitable for the expression of M-CSF and will be readily apparent to one of skill in the art.
      <br/>
      Because of the variability of glycosylation and other post-transnational modifications present in M-CSF produced in certain eukaryotic hosts, expression in E. coli may provide M-CSF with advantageous properties with regard to crystallization.
      <br/>
      Typical in vitro M-CSF expression systems are described in U.S. Pat. No. 4,929,700, for example.
    </p>
    <p num="28">
      For use in the present invention, a variety of M-CSF polypeptides can also be readily designed and manufactured utilizing recombinant DNA techniques well known to those skilled in the art.
      <br/>
      For example, the M-CSF amino acid sequence can vary from the naturally occurring sequence at the primary structure level by amino acid substitutions, insertions, deletions, and the like.
      <br/>
      These modifications can be used in a number of combinations to produce the final modified polypeptide chain.
      <br/>
      The present invention is useful for crystallizing such polypeptides and dimers thereof.
    </p>
    <p num="29">
      In general, modifications of the genes encoding the M-CSF polypeptide are readily accomplished by a variety of well-known techniques, such as site-directed mutagenesis (see, Gillman and Smith, Gene 8:81-97 (1979) and Roberts, S. et al., Nature 328:731-734 (1987) and U.S. Pat. No. 5,032,676, all of which are incorporated herein by reference).
      <br/>
      Most modifications are evaluated by screening in a suitable assay for the desired characteristic.
      <br/>
      For instance, a change in the M-CSF receptor-binding character of the polypeptide can be detected by competitive assays with an appropriate reference polypeptides or by the bioassays described in U.S. Pat. No. 4,847,201, which is incorporated herein by reference.
    </p>
    <p num="30">
      Insertional variants of the present invention are those in which one or more amino acid residues are introduced into a predetermined site in the M-CSF.
      <br/>
      For instance, insertional variants can be fusions of heterologous proteins or polypeptides to the amino or carboxyl terminus of the subunits.
      <br/>
      Substitutional variants are those in which at least one residue has been removed and a different residue inserted in its place.
      <br/>
      Nonnatural amino acids (i.e., amino acids not normally found in native proteins), as well as isosteric analogs (amino acid or otherwise) are also suitable for use in this invention.
      <br/>
      Examples of suitable substitutions are well known in the art, such as the Glu --&gt; Asp, Ser --&gt; Cys, and Cys --&gt; Ser, His --&gt; alanine for example.
      <br/>
      Another class of variants are deletional variants, which are characterized by the removal of one or more amino acid residues from the M-CSF.
    </p>
    <p num="31">
      Other variants of the present invention may be produced by chemically modifying amino acids of the native protein (e.g., diethylpyrocarbonate treatment which modifies histidine residues).
      <br/>
      Preferred or chemical modifications which are specific for certain amino acid side chains.
      <br/>
      Specificity may also be achieved by blocking other side chains with antibodies directed to the side chains to be protected Chemical modification includes such reactions as oxidation, reduction, amidation, deamidation, or substitution of bulky groups such as polysaccharides or polyethylene glycol (see e.g., U.S. Pat. No. 4,179,337 and WO91/21029 both of which are incorporated herein by reference).
    </p>
    <p num="32">
      Exemplary modifications include the modification of lysinyl and amino terminal residues by reaction with succinic or other carboxylic acid anhydrides.
      <br/>
      Modification with these agents has the effect of reversing the charge of the lysinyl residues.
      <br/>
      Other suitable reagents for modifying amino-containing residues include imidoesters such as methyl picolinimidate; pyridoxal phosphate; pyridoxal chloroborohydride; trinitrobenzenesulfonic acid; O-methylisourea; 2,4-pentanedione; and transaminase-catalyzed reaction with glyoxylate, and N-hydroxysuccinamide esters of polyethylenene glycol or other bully substitutions.
    </p>
    <p num="33">
      Arginyl residues may be modified by reaction with a number of reagents, including phenylglyoxal, 2,3-butanedione, 1,2-cyclohexanedione, and ninhydrin.
      <br/>
      Modification of arginine residues requires that the reaction be performed in alkaline conditions because of the high pKa of the guanidine functional group.
      <br/>
      Furthermore, these reagents may react with the groups of lysine as well as the arginine epsilon-amino group.
    </p>
    <p num="34">
      Tyrosyl residues may also be modified with particular interest in, introducing spectral labels into tyrosyl residues by reaction with aromatic diazonium compounds or tetranitromethane are used to form O-acetyl tyrosyl species and 3-nitro derivatives, respectively.
      <br/>
      Tyrosyl residues may also be iodinated using 125 I or 131 I prepare labeled proteins for use in radioimmunoassay.
    </p>
    <p num="35">
      Carboxyl side groups (aspartyl or glutamyl) may be selectively modified by reaction with carbodiimides (R--N.dbd.C.dbd.N--R1), where R and R1 are different alkyl groups, such as 1-cyclohexyl-3-(2-morpholinyl-4-ethyl) carbodiimide or 1-ethyl-3-(4-azonia-4,4-dimethylpentyl)carbodiimide.
      <br/>
      Furthermore, aspartyl and glutamyl residues are converted to asparaginyl and glutaminyl residues by reaction with ammonium ions.
    </p>
    <p num="36">
      Conversely, glutaminyl and asparaginyl residues may be deamidated to the corresponding glutamyl and aspartyl residues, respectively, under mildly acidic conditions.
      <br/>
      Either form of these residues falls within the scope of this invention.
    </p>
    <p num="37">Other modifications include hydroxylation of proline and lysine, phosphorylation of hydroxyl groups of seryl or threonyl residues, methylation of the  ALPHA -amino groups of lysine, arginine, and histidine side chains (T. E. Creighton, Proteins: Structure and Molecular Properties, W. H. Freeman &amp; Co., San Francisco, pp. 79-86 ï¿½1983ï¿½), acetylation of the N-terminal amine, and amidation of any C-terminal carboxyl group.</p>
    <p num="38">
      The availability of a DNA sequence encoding M-CSF permits the use of various expression systems to produce the desired polypeptides.
      <br/>
      Construction of expression vectors and recombinant production from the appropriate DNA sequences are performed by methods well known in the art.
      <br/>
      These techniques and various other techniques are generally performed according to Sambrook et al., Molecular Cloning--A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y. (1989), and Kriegler, M., Gene Transfer and Expression, A Laboratory Manual, Stockton Press, New York (1990), both of which are incorporated herein by reference.
    </p>
    <p num="39">Purification of M-CSF</p>
    <p num="40">
      Purification steps are employed to ensure that the M-CSF is isolated, prior to crystallization, in a relatively homogeneous state.
      <br/>
      In general, a higher purity solution increases the likelihood of success of subsequent crystallization steps.
      <br/>
      Typical purification methods include the use of centrifugation, partial fractionation using salt or organic compounds, dialysis, conventional column chromatography (such as ion-exchange, molecular sizing chromatography etc.), high performance liquid chromatography (HPLC), and gel electrophoresis methods (see, e.g., Deutcher. "Guide to Protein Purification" in Methods in Enzymology (1990), Academic Press, Berkely, Calif., which is incorporated herein by reference for all purposes).
      <br/>
      Preferred purification conditions for generating unusually homogeneous M-CSF species as well as purification of these species are disclosed, for example, in U.S. Pat. No. 4,929,700 which is incorporated herein by reference.
      <br/>
      Other purification methods are known and will be apparent to one of skill in the art.
    </p>
    <p num="41">Crystallization of M-CSF</p>
    <p num="42">
      Although many of the same physical principles govern crystallization of polypeptides (including M-CSF dimers) and small molecules, the actual crystallization mechanisms differ significantly.
      <br/>
      For example, the lattice of small-molecule crystals effectively excludes solvent while that of polypeptide crystals includes substantial numbers of solvent molecules.
      <br/>
      Thus, special techniques must typically be applied to crystallize polypeptides.
    </p>
    <p num="43">
      Polypeptide crystallization occurs in solutions where the polypeptide concentration exceeds its solubility maximum (i.e., the polypeptide solution is supersaturated).
      <br/>
      Such "thermodynamically metastable" solutions may be restored to equilibrium by reducing the polypeptide concentration, preferably through precipitation of the polypeptide crystals.
      <br/>
      Often polypeptides may be induced to crystallize from supersaturated solutions by adding agents that alter the polypeptide surface charges or perturb the interactions between the polypeptide and bulk water to promote associations that lead to crystallization.
    </p>
    <p num="44">
      Compounds known as "precipitants" are often used to decrease the solubility of the polypeptide in a concentrated solution.
      <br/>
      Precipitants induce crystallization by forming an energetically unfavorable precipitant depleted layer around the polypeptide molecules.
      <br/>
      To minimize the relative amount of this depletion layer, the polypeptides form associations and ultimately crystals as explained in Weber, Advances in Protein Chemistry 41:1-36 (1991) which was previously incorporated by reference, In addition to precipitants, other materials are sometimes added to the polypeptide crystallization solution.
      <br/>
      These include buffers to adjust the pH of the solution (and hence surface charge on the peptide) and salts to reduce the solubility of the polypeptide.
      <br/>
      Various precipitants are known in the art and include the following: ethanol, 3-ethyl-2,4-pentanediol; and many of the polyglycols, such as polyethylene glycol.
      <br/>
      A suitable precipitant for crystallizing M-CSF is polyethylene glycol (PEG), which combines some of the characteristics of the salts and other organic precipitants (see, for example, Ward et al., J. Mol. Biol. 98:161 ï¿½1975ï¿½ which is incorporated herein by reference for all purposes and McPherson J. Biol. Chem. 251:6300 ï¿½1976ï¿½, which was previously incorporated by reference).
    </p>
    <p num="45">
      Commonly used polypeptide crystallization methods include the following techniques: batch, hanging drop, seed initiation, and dialysis.
      <br/>
      In each of these methods, it is important to promote continued crystallization after nucleation by maintaining a supersaturated solution.
      <br/>
      In the batch method, polypeptide is mixed with precipitants to achieve supersaturation, the vessel is sealed and set aside until crystals appear.
      <br/>
      In the dialysis method, polypeptide is retained in a sealed dialysis membrane which is placed into a solution containing precipitant.
      <br/>
      Equilibration across the membrane increases the polypeptide and precipitant concentrations thereby causing the polypeptide to reach supersaturation levels.
    </p>
    <p num="46">
      In the hanging drop technique, an initial polypeptide mixture is created by adding a precipitant to concentrated polypeptide solution.
      <br/>
      The concentrations of the polypeptide and precipitants are such that in this initial form, the polypeptide does not crystallize.
      <br/>
      A small drop of this mixture is placed on a glass slide which is inverted and suspended over a reservoir of a second solution.
      <br/>
      The system is then sealed.
      <br/>
      Typically the second solution contains a higher concentration of precipitant or other dehydrating agent.
      <br/>
      The difference in the precipitant concentrations causes the protein solution to have a higher vapor pressure than the solution.
      <br/>
      Since the system containing the two solutions is sealed, an equilibrium is established, and water from the polypeptide mixture transfers to the second solution.
      <br/>
      This equilibration increases the polypeptide and precipitant concentration in the polypeptide solution.
      <br/>
      At the critical concentration of polypeptide and precipitant, a crystal of the polypeptide will form.
      <br/>
      The hanging drop method is well known in the art (see, McPherson J. Biol. Chem. 251:6300 ï¿½1976ï¿½, which was previously incorporated herein by reference).
    </p>
    <p num="47">
      Another method of crystallization introduces a nucleation site into a concentrated polypeptide solution.
      <br/>
      Generally, a concentrated polypeptide solution is prepared and a seed crystal of the polypeptide is introduced into this solution.
      <br/>
      If the concentrations of the polypeptide and any precipitants are correct, the seed crystal will provide a nucleation site around which a larger crystal forms.
    </p>
    <p num="48">
      In preferred embodiments, the crystals of the present invention will be formed from a dimer of M-CSF polypeptides.
      <br/>
      Preferred crystals are typically at least about 0.2 * 0.2 * 0.05 mm, more preferably larger than 0.4 * 0.4 * 0.4 mm, and most preferably larger than 0.5 * 0.5 * 0.5 mm. After crystallization, the protein may be separated from the crystallization mixture by standard techniques.
    </p>
    <p num="49">
      The crystals so produced have a wide range of uses.
      <br/>
      For example, high quality crystals are suitable for X-ray or neutron diffraction analysis to determine the three-dimensional structure of the M-CSF and, in particular, to assist in the identification of its receptor binding site.
      <br/>
      Knowledge of the binding site region and solvent-accessible residues available for contact with the M-CSF receptor allows rational design and construction of agonists and antagonist for M-CSFs.
      <br/>
      Crystallization and structural determination of M-CSF muteins having altered receptor binding ability or bioactivity allows the evaluation of whether such changes are caused by general structural deformation or by side chain alteration at the substitution site:.
    </p>
    <p num="50">
      In addition, crystallization itself can be used as purification method.
      <br/>
      In some instances, a polypeptide or protein will crystallize from a heterogeneous mixture into crystals.
      <br/>
      Isolation of such crystals by filtration, centrifugation, etc. followed by redissolving the polypeptide affords a purified solution suitable for use in growing the high-quality crystals necessary for diffraction studies.
      <br/>
      These high-quality crystals may also be dissolved in water and then formulated to provide an aqueous M-CSF solution having various uses known in the art including pharmaceutical purposes.
    </p>
    <p num="51">
      Of course, amino acid sequence variants of M-CSF may also be crystallized and used.
      <br/>
      These mutants can be used for, among other purposes, obtaining structural information useful for directing modification of the binding affinity for M-CSF receptors.
      <br/>
      As with the naturally occurring forms, the modified M-CSF forms may be useful as pharmaceutical agents for stimulating bone marrow proliferation, overcoming immune suppression and fungal diseases induced by chemotherapy, improving therapeutic efficacy, and lessening the severity or occurrence of side effects during therapeutic use of the present invention.
      <br/>
      Furthermore, modified M-CSFs may be useful for treatment of disease in which soluble or membrane-bound M-CSF causes or exacerbates the disease state.
    </p>
    <p num="52">Characterization of M-CSF</p>
    <p num="53">
      After purification, crystallization and isolation, the subject crystals may be analyzed by techniques known in the art.
      <br/>
      Typical analysis yield structural, physical, and mechanistic information about the peptides.
      <br/>
      As discussed above, X-ray crystallography provides detailed structural information which may be used in conjunction with widely available molecular modeling programs to arrive at the three-dimensional arrangement of atoms in the peptide.
      <br/>
      Exemplary modeling programs include "Homology" by Biosym (San Diego, Calif.), "Biograf" by BioDesign, "Nemesis" by Oxford Molecular, "SYBYL" and "Composer" by Tripos Associates, "CHARM" by Polygen (Waltham, Mass.), "AMBER" by University of California, San Francisco, and "MM2" and "MMP2" by Molecular Design, Ltd.
    </p>
    <p num="54">
      Peptide modeling can be used to design a variety of agents capable of modifying the activity of the subject peptide.
      <br/>
      For example, using the three-dimensional structure of the active site, agonists and antagonists having complementary structures can be designed to enhance the therapeutic utility of M-CSF treatment or to block the biological activity of M-CSF.
      <br/>
      Further, M-CSF structural information is useful for directing design of proteinaceous or non-proteinaceous M-CSF agonists and antagonists, based on knowledge of the contact residues between the M-CSF ligand and its receptor.
      <br/>
      Such residues are identified by the M-CSF crystal structure as those which are solvent-accessible, distal to the carboxyl terminal membrane anchoring region not involved in dimer interface stabilizations, and possibly including residues not conserved between human and mouse M-CSF (which does not recognize the human M-CSF receptor).
    </p>
    <p num="55">EXAMPLE 1</p>
    <p num="56">
      Systematic crystallization trials with M-CSF were made using the hanging drop technique.
      <br/>
      A microdroplet (5  MU l) of mother liquor is suspended from the underside of a microscope cover slip, which is placed over a well containing 1 ml of the precipitating solution. 60-70 initial trials were set up, in which pH, temperature, counterion and precipitant were varied.
      <br/>
      From these trials, the few that gave promising microcrystals were picked for more careful examination.
    </p>
    <p num="57">
      It was discovered that suitable crystals may be grown from a 20  MU l drop containing: 10 mg/ml protein, 100 mM MgCl2, 50 mM Tris.Cl, pH 8.5, and 12% PEG 4000.
      <br/>
      This drop was equilibrated against a reservoir containing 24% PEG 4000.
      <br/>
      Tiny, needle-like crystals appeared in 2-3 days which were redissolved in 10  MU l water and recrystallized at room temperature.
      <br/>
      Good quality chunky crystals appeared in 7-9 days in sizes ranging from 0.3 * 0.3 * 0.3 mm to 0.5 * 0.5 * 1.0 mm.
    </p>
    <p num="58">
      Precession photographs revealed the space group to be P21 21 21 with unit cell dimensions: a=33.53  Angstrom , b=65.11  Angstrom , c=159.77  Angstrom .
      <br/>
      This gives a unit cell volume of 349084.5  Angstrom 3, which is consistent with a dimer in the crystallographic asymmetric unit, and 52% of the unit cell volume being occupied by solvent.
      <br/>
      The crystals diffracted to a resolution of 3  Angstrom  on a Rigaku rotating anode X-ray generator (Danvers, Mass.) operated at 50 kV and 60 mA, and to 2.6  Angstrom  in synchrotron radiation.
    </p>
    <p num="59">
      Screening for heavy atom derivatives was done by soaking crystals into solutions of heavy-metal salts.
      <br/>
      Zero-level precession pictures of the soaks were used to identify potential derivatives.
      <br/>
      About 30 different soaking conditions were examined, of which 4 potential derivatives were identified.
      <br/>
      Unfortunately, some soaks caused the crystals to exhibit non-isomorphism (i.e., the heavy atom soaks induced a change in cell dimensions, making them unusable for phase calculation).
    </p>
    <p num="60">
      Three-dimensional intensity data were collected on film using an oscillation camera on the X-ray beam-line at the National Synchrotron Light Source, Brookhaven.
      <br/>
      Several other data sets, of native (underivatized M-CSF) as well as potential derivative crystals have been collected on a Rigaku X-ray generator.
      <br/>
      The following data sets were collected.
    </p>
    <p num="61">
      --
      <br/>
      --                Resolution N             N
      <br/>
      -- Crystal        ( Angstrom ) (observations) (unique) X-Ray Source
      <br/>
      -- Native         2.8       27922         7311    Synchrontron
      <br/>
      -- Native         2.9       35236         7002    Rigaku
      <br/>
      --                                                (film)
      <br/>
      -- Native         3.5        5144    5116    Rigaku
      <br/>
      --                                                (diffractometer)
      <br/>
      -- K2 Hg(SCN)4  3.5       15885         4119    Rigaku
      <br/>
      --                                                (film)
      <br/>
      -- UO2 Cl2  3.5       25492         5048    Rigaku
      <br/>
      --                                                (film)
      <br/>
      -- Cis-Pd(NH3)2 Cl2  3.1       26122         6304
      <br/>
      --  Synchrotron
    </p>
    <p num="62">EXAMPLE 2</p>
    <p num="63">
      Recombinant M-CSF polypeptides were purified from E. coli. and renatured to form a disulfide-linked dimeric protein as described in U.S. Pat. No. 4,929,700. Crystallization of the resulting unglycosylated M-CSF ALPHA  protein (amino acids 4-158 in homodimeric form) was performed by the hanging drop method.
      <br/>
      Glass microscope plates were siliconized prior to use by dipping immersion into a 1% (volume:volume) solution of the organosilane compound, Prosil-28 (PCR Incorporated, Gainesville, Fla., 32602) washing the treated glass plates with water, and baking at 180 degrees.
    </p>
    <p num="64">
      A 2 mg/ml aqueous solution of purified human recombinant M-CSF was dialyzed and concentrated against 50 mM Tris-HCl (pH 8.5) using a dialysis tubing having a 10 kD cutoff.
      <br/>
      The final concentration of polypeptide (10 mg/ml) was determined by ultraviolet spectrophotometry at 280 nm.
    </p>
    <p num="65">
      About 7 microliters of the concentrated solution was mixed in each well of the spot plate with 7 microliter of 20% (v/v) PEG 4000, 0.2 M MgCl2, 0.1 M Tris-HCl (pH 8.5).
      <br/>
      The spot plate was then placed in a clear plastic sandwich box containing 20 ml of 23% PEG 4000, 0.2 M MgCl2, 0.1 M Tris-HCl (pH 8.5) and the box was immediately scaled and stored at room temperature.
      <br/>
      Minor variations in this procedure such as altering buffer conditions are within the scope of the present invention.
      <br/>
      For example, in a preferred embodiment of the present invention, buffer conditions were altered to include 150 mM MgCl2 and 24% PEG 4000.
    </p>
    <p num="66">
      After 3-5 days, small microcrystals having a size of 0.1 * 0.1 * 0.05 mm appeared in each well.
      <br/>
      These microcrystals were isolated and redissolved in 25 microliter of 50 mM Tris-HCl and allowed to stand at room temperature.
      <br/>
      The purified M-CSF crystallized from solution into large hexagonal prism shaped crystals ranging in size from 0.3 * 0.3 * 0.3 mm to 1 mm * 2 mm * 0.5 mm. These crystals were stable at room temperature for at least three months.
      <br/>
      In some instances, an artificial mother liquor was prepared using 23% PEG 4000 and 150 mM MgCl2 crystals were then added to this mother liquor.
      <br/>
      In these cases, the crystals were removed from the mother liquor immediately prior to analysis.
    </p>
    <p num="67">
      Using reducing and non-reducing SDS-PAGE analysis, the M-CSF in the crystals was shown to be identical in molecular weight to the biologically active starting material.
      <br/>
      Thus, the M-CSF structure obtained from the crystals is likely to be essentially identical to the structure of biologically active M-CSF.
    </p>
    <p num="68">EXAMPLE 3</p>
    <p num="69">
      Glass microscope slides were prepared as described in Example 2. 7 microliters of the same concentrated M-CSF ALPHA  protein solution was mixed in each well of the spot plate with 7 microliter of 30% (v/v) PEG 4000, 0.2 M ammonium acetate, 0.1 M acetate buffer (pH 7.5).
      <br/>
      The spot plate was then placed in a clear plastic sandwich box containing 20 ml of 30% PEG 4000, 0.2 M ammonium acetate, 0.1 M acetate buffer (pH 7.5) and the box was immediately sealed and stored at room temperature.
      <br/>
      After 3-5 days, thin, plate-like, fragile crystals having a size of approximately 0.3 * 0.3 * 0.05 mm appeared.
    </p>
    <p num="70">EXAMPLE 4</p>
    <p num="71">Preliminary X-ray Analysis</p>
    <p num="72">
      X-ray crystallographic analysis using precession photographs showed that the crystals produced in Example 2 have an orthorhombic crystal lattice in the P21 21 21 space group with cell dimensions a=33.54, b=65.26, c=159.63 d=90.0, c=90.0 and f=90.0 angstroms and diffract to a nominal resolution of 2.6 angstroms using synchrotron radiation.
      <br/>
      These data provided a unit cell volume of 348084.5 angstroms3, which is consistent with a dimer in the crystallographic asymmetric unit with 52% of the unit cell volume being occupied by solvent.
      <br/>
      FIG. 1 is a 12-degree precession photograph of the Ok1-zone section of the M-CSF crystal.
      <br/>
      The photograph was taken using a precession camera manufactured by Enraf-Nonius Company (Delft, Holland), mounted on a Rigaku RU-200 X-ray generator operated at 50 kV and 50 mA.
    </p>
    <p num="73">EXAMPLE 5</p>
    <p num="74">Testing of M-CSF Receptor Binding Ability Using Soluble M-CSF Receptor</p>
    <p num="75">
      An essential step in the biological function of M-CSF in vivo is the binding to the M-CSF receptor, also referred to as the c-fms gene product.
      <br/>
      Recombinant human soluble M-CSF receptor (rhsM-CSFR), representing amino acids; 20 to 511 SEQ ID NO:11 (Coussens, L et al., Nature, 320:277 (1986)) was used as an in vitro assay reagent to test the receptor-binding ability of M-CSF proteins.
      <br/>
      To generate a soluble form of the transmembrane receptor, only the extracellular domain of the human M-CSF receptor was expressed in a baculovirus/insect cell recombinant expression system.
      <br/>
      In order to purify the soluble receptor without adversely effecting tertiary or quaternary structure, non-denaturing chromatographic methods were chosen, as described below.
      <br/>
      Other choices exist for the purification of the recombinant receptor.
      <br/>
      Affinity chromatography may be employed when either a suitable antibody to or ligand for the receptor are available.
      <br/>
      Alternatively, "tags" may be added to the C-terminus of the recombinant receptor, i.e., KT3 antibody recognition sequence, and purified by an anti-tag antibody, i.e., KT3, column, for use in affinity chromatography.
      <br/>
      In expression systems in which the rhsM-CSFR is glycosylated, lectin chromatography can be used to enrich for specific glycoproteins.
    </p>
    <p num="76">
      The rhsM-CSFR can be used to study ligand/receptor interactions as well as ligand-induced receptor dimerization.
      <br/>
      The assay used to detect ligand/receptor binding employed the use of size exclusion-HPLC, essentially as described in European Patent Application WO92/21029, C. Cunningham, et al., with the following modifications: the column used was a Superose 6 (Pharmacia LKB Biotechnology, Inc.) and the mobile phase was PBS at 0.5 ml/min and a M-CSF to rhsM-CSFR ratio of 1:2.
      <br/>
      At this ratio, the M-CSF/rhsM-CSFR complex chromatographed with an apparent hydrodynamic radius of 190,000 molecular weight, the molecular weight expected for a M-CSF(rhsM-CSFR)2 complex.
      <br/>
      Other assays may be employed to measure ligand/receptor binding or receptor dimerization such as chemical crosslinking and SDS-PAGE or immunoprecipitation and SDS-PAGE.
      <br/>
      Molecules that inhibit receptor dimerization but not ligand binding provide another method to antagonize M-CSF actions.
    </p>
    <p num="77">
      The DNA encoding rhsM-CSFR was cloned for expression in insect cells using the following general strategy.
      <br/>
      The portion of the c-fms gene corresponding to amino acids one to 511 was amplified from human macrophage cDNA by polymerase chain reaction (PCR) using an upstream primer of: 5'-GCGTACCATGGGCCCAGGAGTTCTGC-3' (SEQ ID NO. 9) and a downstream primer of: 5'-AGTCGAGGATCCTCAATCCGGGGGATGCGTGTG-3' (SEQ ID NO. 10).
      <br/>
      The underlined sequences are the NcoI and BamHI restriction sites used to subclone the PCR product into the pAcC5 vector (Luckov et al., Bio/Technology 6:47-55).
      <br/>
      The pAcC5:hsM-CSFR vector was expressed in SF9 insect cells using a baculovirus helper vector as previously described (Summers, et al., A Manual of Methods for Baculovirus Vectors and Insect Cell Culture Procedures (1987)).
    </p>
    <p num="78">
      Approximately two liters of serum-free 72-hour conditioned medium was collected by centrifugation and filtration from SF9 cells infected with pAcC5:hsM-CSFR construct described above.
      <br/>
      The material was diafiltered with DEAE buffer A ï¿½10 mM Tris, pH 8.8, containing the following protease inhibitors (which were added all buffers throughout the purification): 1 mM EDTA, 2  MU g/ml leupeptin and 100  MU M PMSFï¿½ and concentrated 20-fold with a 20,000 molecular weight cutt-off Pyrostat Ultrafiltration Membrane (Sartorius).
      <br/>
      The retentate was loaded onto a DEAE Sepharose column (Pharmacia LKB Biotechnology, Inc., Piscataway, N.J.) having a bed volume of 100 ml that had been pre. equilibrated with DEAE Buffer A. Elution was at 5 ml/min with a 0-0.8 M NaCl gradient in 500 ml of DEAE Buffer A. Fractions enriched in rhsM-CSFR were detected Western Analysis ï¿½Burnett, R., Anal. Biochem., 112:195 (1981)ï¿½ and dot blot analysis of serially diluted fractions, using anti-c-fms monoclonal antibodies (Oncogene Sciences, Inc.).
      <br/>
      The dot blot assay was used throughout the purification to identify fractions containing rhsM-CSF.
      <br/>
      Enriched fractions were pooled, made 0.8 M in ammonium sulfate, adjusted to pH 7.0 and loaded onto a Phenyl TSK-5-PW HPLC column (7.5 * 75 mm) (BioRad).
      <br/>
      The column was eluted at 1 ml/min with a decreasing ammonium sulfate gradient over 45 minutes, peak fractions were pooled and concentrated 10-fold with a stir cell concentrator using a YM30 membrane (Amicon).
      <br/>
      The retentate was chromatographed with FG3000XL size exclusion column (DU PONT, Wilmington, Del.) using a mobile phase a phosphate-buffered saline (PBS) at 3 ml/min.
      <br/>
      The purified receptor was pooled, concentrated to 1 mg/ml as above and stored at 4 (degree)  C. This process recovered 650  MU g of rhsM-CSFR, purified 200-fold.
      <br/>
      The preparation was about 95% homogeneous as assayed by SDS-PAGE stained with Coomassie Blue.
    </p>
    <p num="79">EXAMPLE 6</p>
    <p num="80">Crystallization of M-CSF/Soluble M-CSF Receptor Complex</p>
    <p num="81">
      To crystallize the M-CSF/rhsM-CSFR complexes, glass microscope slides are prepared as described in Example 2.
      <br/>
      The M-CSF composition used is incubated with a purified soluble form of the M-CSF receptor, truncated at a residue before the transmembrane region, to form an M-CSF/receptor complex.
      <br/>
      In certain cases, the rhsM-CSFR is deglycosylated prior to the size exclusion step by incubation with N-glycanase (Genzyme, Cambridge Mass.) according to the manufacturer's instructions.
      <br/>
      A small quantity of M-CSF/receptor solution is mixed in each well of the spot plate with a comparable quantity of a drop solution (such as about 20% (v/v) PEG 4000, 0.2 M MgCl2, 0.1 M Tris-HCl (pH 8.5)).
      <br/>
      The spot plate is then placed in a clear plastic sandwich box containing a small amount of precipitant solution (such as about 23% PEG 4000, 0.2 M MgCl2, 0.1 M Tris-HCl (pH 8.5)).
      <br/>
      The box is immediately sealed and stored at room temperature.
    </p>
    <p num="82">
      After a few days, crystalline M-CSF-receptor complex is isolated and redissolved in a solution containing about 50 mM Tris-HCl and is allowed to stand at room temperature.
      <br/>
      The purified M-CSF-receptor complex crystallizes from solution to form crystals for X-ray structural analysis.
      <br/>
      To facilitate solution of the crystal structure of such complexes, truncated, non-glycosylated forms of the rhsM4-CSFR (described above) which retain M-CSF binding ability may be employed to generate M-CSF-receptor complex crystals.
    </p>
    <p num="83">EXAMPLE 7</p>
    <p num="84">
      The biological activity of the non-glycosylated, truncated sequence used in Examples 2 and 3 was shown to be equal to that of the mature protein purified from human urine (Halenbeck, R., et al., Bio/Technology, 7:710-715 ï¿½1989ï¿½).
      <br/>
      As noted, the resulting crystals had an orthorhombic crystal lattice in the P21 21 21 space group, with cell dimensions a=33.54, b=65.26, and c=159.63  Angstrom .
      <br/>
      Intensity data were collected using imaging plates mounted on a Weissenberg camera modified for macromolecular crystallography at the Photon Factory in Tsukuba, Japan.
      <br/>
      Native data to a nominal resolution of 2.0  Angstrom , and mercury and platinum derivative data were collected using 1.0  Angstrom  radiation.
      <br/>
      Two crystal settings were used to collect native data ï¿½Rmerge (I)=7.0%, using all measurements with I&gt;0.0ï¿½.
    </p>
    <p num="85">
      Heavy atom derivatives of M-CSF crystals were prepared by soaking crystals in heavy atom compounds dissolved in the reservoir solution.
      <br/>
      Isomorphous and anomalous difference Patterson maps clearly revealed one site for the mercury and two sites for the platinum derivative.
      <br/>
      Anomalous and isomorphous phase information as used in initial phase refinement with the PROTEIN program package.
      <br/>
      The final figure of merit was 0.62 (8.0-3.0  Angstrom , 6960 reflections).
      <br/>
      After solvent flattening, B. C. Wang, Methods Enzymol, 115:90 (1985), two bundles of four alpha helices related by an approximate two-fold axis could be seen in the electron density map.
      <br/>
      Rotation and translation parameters of this non-crystallographic axis were refined by a density correlation method, J. M. Cox, J. Mol. Biol. 28:151 (1967).
      <br/>
      Phases were then iteratively refined by molecular averaging and solvent flattening, G. Bricogne, Acta Cryst., 32:832 (1976), using an envelope calculated by putting 5  Angstrom  spheres around all the atoms in the four helical bundle.
      <br/>
      Chain racing and model building were done in the resulting map, (using the program FRODO), T. A. Jones, Methods Enzymol. 115:157 (1985), keeping the original MIR map as a reference.
    </p>
    <p num="86">
      The starting partial model for refinement contained only a polyalanine backbone for eight helices making up the two bundles.
      <br/>
      Positional refinement using the program XPLOR, A. T. Brunger, J. Mol. Biol. 203:803 (1985), gave an R-factor of 0.49 to 3.0  Angstrom .
      <br/>
      Phase combination with the refined MIR phases resulted in a map of sufficient quality to allow the tracing of two long loops traversing the four helical bundle and a short loop connecting two of the helices.
      <br/>
      Two strong peaks in the density, one at the top of the first helix, and the second lying directly on the molecular two fold axis, were assigned as disulfide bonded cysteines.
      <br/>
      The number of residues between these two peaks uniquely identified the position in the sequence of these cysteines and consequently the sequence of the intervening residues.
      <br/>
      This initial registration was confirmed by the presence of a number of regions of strong density corresponding to aromatic side chains in the sequence.
      <br/>
      Partial model phase combination using the added loops and those side chains that were visible allowed the remaining residues to be registered, thus determining the overall topology of the molecule.
      <br/>
      The presence of seven disulfide bonds in the dimer served as important "tether points" to confirm the correctness of the tracing.
    </p>
    <p num="87">
      As shown in FIG. 2, the overall topology of this form of M-CSF is that of an antiparallel four  ALPHA -helical bundle, in which the helices run up-up-down-down, unlike the more commonly observed up-down-up-down connectivity of most four helical bundles.
      <br/>
      A long crossover connection links helix A to helix B and a similar connection is found between helices C and D.
    </p>
    <p num="88">
      A striking difference from other cytokines and other four helix bundle structures is that the truncated M-CSF ALPHA  forms a disulfide-linked dimer, in which the bundles are linked end-to-end, forming an extremely flat, elongated structure (approximate dimensions 85 * 35 * 25  Angstrom ) as shown in FIGS. 3 and 4A and 4B.
      <br/>
      There are three intramolecular disulfide bonds in each monomer (Cys7-Cys90, Cys8-Cys139, Cys102-Cys146) all of which are at the distal end of the molecule.
      <br/>
      One interchain disulfide bond (Cys31--Cys31) is located at the dimer interface with the noncrystallographic two-fold symmetry axis passing through it as shown in FIGS. 3 and 4.
      <br/>
      Mutation experiments indicate that all of the cysteine residues in this form of M-CSF may be necessary for full biological activity.
      <br/>
      The structure described herein suggests that their role is primarily structural rather than being related to receptor recognition.
    </p>
    <p num="89">
      Appendix 1 provides the three-dimensional structure of the truncated, recombinant M-CSF ALPHA  dimer as identified by the alpha carbon positions of the amino acid residues in the sequence.
      <br/>
      The five carboxy terminal amino acids of each polypeptide of the dimer were not included.
      <br/>
      As will be recognized to those of skill in the art, the information in Appendix 1 is provided in the format used by the Brookhaven Protein Data Bank.
    </p>
    <p num="90">
      As shown, the molecule has an unusual topology which identifies important regions of M-CSF with regard to M-CSF receptor binding.
      <br/>
      Specific residues in helices A, C, and D appear to be involved in the specificity of the interaction.
      <br/>
      Altering solvent accessible residues in these regions by site directed mutagenesis to increase or decrease side-chain interactions with the receptor may be useful to generate M-CSF agonists or antagonists.
      <br/>
      For example, changing one or more histidines to non-hydrogen-donor amino acids of similar size may create an M-CSF with altered receptor binding ability.
    </p>
    <p num="91">EXAMPLE 8</p>
    <p num="92">Preparation of M-CSF Heterodimers</p>
    <p num="93">Purification of M-CSF Monomers</p>
    <p num="94">
      E. coli harboring the pL-M-CSF vector for N DELTA 3C DELTA 158M-CSF ALPHA  described in U.S. Pat. No. 4,929,700 or N DELTA 3C DELTA 221 M-CSF BETA  C157S, C159S (Kawasaki, et al., in Colony-Stimulating Factors, Dexter, T., Garland, J., and Testa, N., eds. ï¿½1990ï¿½) were grown in 1 liter of minimal salts medium containing glucose and the appropriate antibiotic.
      <br/>
      Expression of M-CSF was induced by shifting the temperature to 39 (degree)  C. for 4 hr. following the addition of casamino acids to 2%.
      <br/>
      The cells were harvested by centrifugation and lysed by sonication in 50 mM Tris (pH 8.5), 10 mM EDTA.
      <br/>
      The cell debris was recovered by centrifugation, washed with 30% sucrose containing 10 mM EDTA, and a portion of the refractile body paste was solubilized in 8 M urea under reducing conditions.
      <br/>
      After incubation at 37 (degree)  C. for 30 min., the solubilized M-CSF was clarified by centrifugation and filtration, and then loaded onto a Bio-Gel TSK-DEAE-5-PW column (7.5 * 75 mm) (BioRad Laboratories, Richmond, Calif.) equilibrated in 8 M urea in 10 mM Tris (pH 8.5), 5 mM DTT, 0.5 mM EDTA. The monomeric M-CSF was eluted with a 45-min, 0-0.6 M NaCl gradient.
      <br/>
      The M-CSF peak fractions were pooled and concentrated to 10 mg/ml with a Centricon 10 microconcentrator (Amicon).
    </p>
    <p num="95">Formation and Analysis of Active M-CSF Heterodimers</p>
    <p num="96">
      The M-CSF homodimers were refolded by diluting to a protein concentration of 0.5 mg/ml in precooled 50 mM Tris (H 8.5), 5 mM EDTA, 2 mM reduced glutathione and 1 mM oxidized glutathione, and then incubating at 4 (degree)  C. The heterodimer was refolded by diluting 158 and 221F monomer pools to 1 mg/ml in the same buffer.
      <br/>
      To monitor the refolding, size exclusion high pressure liquid chromatography (SE-HPLC) analysis was performed by immediately injecting reaction samples onto a G3000SW Ultropack (Pharmacia LKB Biotechnology, Inc., Piscataway, N.J.) column size-exclusion (7.5 * 600 mm) equilibrated in PBS (pH 6.8).
    </p>
    <p num="97">
      Fractionated products were analyzed on reducing SDS-PAGE and stained with Coomassie, according to the method of Laemmli, Nature (Canada) 227:680-685 (1970).
      <br/>
      Biological activity was determined using the M-CSF dependent NFS-60 bioassay (See Example 10 below).
      <br/>
      Antibody neutralization experiments were carried out by pre-incubating approximately 5,000 units of M-CSF dimer with varying dilutions of the neutralizing M-CSF 5H410 Mab (made to refolded E. coli C DELTA 150 M-CSF ALPHA  dimer) prior to bioassay. (Halenbeck et al, Bio/Technology 7:710 (1989)
    </p>
    <p num="98">
      The heterodimeric M-CSF product was designed to consist of one chain of short clone (from amino acid 4 to 158) and one chain of long clone (from amino acid 4 to 221).
      <br/>
      The long-clone chain (221F) also contained substitutions of serine for the two non-essential cysteines (at 157 and 159) to minimize the possibility of higher-order oligomer formation.
    </p>
    <p num="99">
      Solubilized refractile bodies of M-CSF 158 and 221F were separately chromatographed by DEAE-HPLC in 8 M urea.
      <br/>
      Only one major protein peak eluted in each case, and the peak fractions were pooled, based on an analysis of purity by non-reducing SDS-PAGE and Coomassie staining (data not shown).
      <br/>
      The resulting monomer was over 90% pure in each case.
      <br/>
      The monomers were separately concentrated to 10 mg/ml, diluted in refolding buffer, and refolded at 4 (degree)  C.
    </p>
    <p num="100">
      To compare the rates of dimerization of shorn- and long-clone M-CSF, 20  MU l of each refolding reaction was injected on a SE-HPLC column at 0, 2. 18 and 72 hr.
      <br/>
      The amount of dimeric M-CSF formed was determined from the peak area at the molecular weight expected for dimer.
      <br/>
      In both refolding reactions the M-CSF was mostly equilibrated to monomer at t=0 and had become about 40% dimeric by 2 hr and nearly 75% dimeric by 18 hr.
      <br/>
      The similarity of the ratio of dimer to monomer between the refolded 158 and 221F strongly suggests that the rate of dimer formation is the same for long- and short-clone M-CSF.
      <br/>
      Thus, when equal moles of 158 and 221F are present in a refolding reaction, the final relative ratios of 158 homodimer to 221F homodimer to 158/221F heterodimer are predicted to be 1:1:2 (Similar distributions have been observed in vivo for isozymes of lactate dehydrogenase.)
    </p>
    <p num="101">Biological Activity of Refolded Homodimers and Heterodimers</p>
    <p num="102">
      The biological activity of the refolded homodimers and heterodimers described above, was examined using the in vitro M-CSF-dependent NFS-60 bioassay (See Example 10 below).
      <br/>
      FIGS. 5A-5C show the result of these studies.
      <br/>
      These SE-HPLC and biological activity profiles analyzed after 72 hr of refolding, show that the heterodimer, FIG. 5C, displays activity very similar to that of the two homodimers, (FIGS. 5A and 5B).
      <br/>
      Given that the separation of the heterodimer from the homodimers was nearly complete, it can be concluded that the heterodimer is fully biologically active in vitro.
    </p>
    <p num="103">
      To verify that the M-CSF protein eluting from these columns at the predicted heterodimeric position (between the two homodimers) actually did consist of equal moles of short- and long-clone monomers, analysis of a preparative purification of the 158/221F heterodimer was carried out.
      <br/>
      Phenyl-HPLC was performed as described above and was shown to completely resolve the heterodimer from the 158 and 221F homodimers, as seen in FIG. 6A.
    </p>
    <p num="104">Preparative Purification of M-CSF Heterodimers</p>
    <p num="105">
      The refolded M-CSF was adjusted to pH 7.0 with 1 N HCl, and ammonium sulfate was added to 1.2 M. The protein was loaded onto a Bio-Gel TSK-Phenyl-5-PW column (7.5 * 75 mm) (BioRad, Richmond, Calif.) equilibrated in 1.2 M ammonium sulfate, 100 mM phosphate (pH 7.0).
      <br/>
      The M-CSF was eluted with a decreasing gradient of ammonium sulfate from 40% to 80% buffer B (10 mM phosphate, pH 7.0) in 24 min.
    </p>
    <p num="106">
      Reducing and non-reducing SDS-PAGE (FIGS. 6B and C) showed that internal controls (the 158 and 221F dimers) were purified to approximately 95% homogeneity by this column, and each consisted of the single expected monomeric band.
      <br/>
      The gel analysis also showed that the heterodimer was purified to approximately 95% homogeneity and that it consisted of equivalent amounts of 158 and 221F monomers.
      <br/>
      Recovery of purified 158/221F heterodimer from refractile body paste to final product, was greater than 15%.
    </p>
    <p num="107">
      The bioactivity of the dimeric M-CSF species was determined and, when compared to the A280 profile in FIG. 6A, confirms the finding that the heterodimer is fully active.
      <br/>
      The specific activity of the 158/221F heterodimer, calculated using the peak fraction, was 8.0 * 107 units/mg, compared to 9.0 * 107 and 6.8 * 107 units/mg for 158 and 221F homodimers, respectively.
    </p>
    <p num="108">
      The biological activity of all three dimer species was neutralized to the same extent in serial dilution neutralization experiments using the 5H410 M-CSF Mab in the NFS-60 bioassay.
      <br/>
      This antibody also neutralizes "naturally refolded" Chinese hamster ovary cell (CHO)-expressed M-CSF in a similar fashion.
      <br/>
      This result further suggests that the refolded conformation of the new M-CSF heterodimer is essentially native-like, at least with regard to the region within the first 150 amino acids that is responsible for in vitro activity.
    </p>
    <p num="109">EXAMPLE 9</p>
    <p num="110">Selection of Amino Acid Substitutions in M-CSF Based on Crystallographic Data</p>
    <p num="111">
      The X-ray crystallographic data described above provided sufficient structural information regarding M-CSF to be able to identify a limited subset of the amino acids in the protein that are likely to be crucial for M-CSF receptor binding and biological activity and thus which represented likely candidates for mutagenesis with the ultimate goal of providing M-CSF muteins having altered biological activity (i.e., agonists or antagonists).
      <br/>
      Based on this information, several criteria were used to generate a list of possible target amino acids for substitution.
    </p>
    <p num="112">
      The first criterion was solvent exposure or solvent accessibility, which refers to amino acids residues at the surface of the protein.
      <br/>
      Residues having a solvent accessible surface area of greater than about 0.25 and preferably greater than about 0.4 are preferred based on normalization of the surface area of the amino acid accessible when in the trypeptide gly-x-gly (Kabsch, W. et al., Biopolymers 22:2577 (1983)).
      <br/>
      Residues were chosen which do not interact with other parts of the protein such as the dimer interface in order to maintain the relative orientation of monomers and to avoid disturbing the process of protein folding.
      <br/>
      Still another criterion used in certain instances in selecting candidate amino acid substitutions is the relationship of the residues to corresponding residues in mouse M-CSF.
      <br/>
      Another important selection criterion was that the substitutions be non-conservative so as to attempt to disrupt possible hydrogen bonding or hydrophobic interactions with M-CSF receptor residues.
    </p>
    <p num="113">
      Table 1 lists exemplary amino acid residues and exemplary substitutions.
      <br/>
      Using the criteria for selecting candidates for substitutions set forth above, those of ordinary skill in the art may readily ascertain other possible candidates for substitution.
    </p>
    <heading>-- TABLE I</heading>
    <p num="114">
      -- Candidate Substitutions
      <br/>
      --      Wild Type Amino Acid and Location Substitutions
      <br/>
      --      His (H) 15                       Ala (A) or Leu (L)
      <br/>
      --      Gln (Q) 17                       Ala (A) or Glu (E)
      <br/>
      --      Gln (Q) 79                       Ala (A) or Asp (D)
      <br/>
      --      Arg (R) 86                       Glu (E) or Asp (D)
      <br/>
      --      Glu (E) 115                      Ala (A)
      <br/>
      --      Glu (E) 41                       Lys (K) or Arg (R)
      <br/>
      --      Lys (K) 93                       Ala (A) or Glu (E)
      <br/>
      --      Asp (D) 99                       Lys (K) or Arg (R)
      <br/>
      --      Leu (L) 55                       Gln (Q) or Asp (N)
      <br/>
      --      Ser (S) 18                       Ala (A) or Lys (K)
      <br/>
      --      Gln (Q) 20                       Ala (A) or Asp (D)
      <br/>
      --      Arg (R) 21                       Ala (A), Glu (E),
      <br/>
      --                                       or Asp (D)
      <br/>
      --      Ile (I) 75                       Lys (K) or Glu (E)
      <br/>
      --      Val (V) 78                       Lys (K) or Arg (R)
      <br/>
      --      Leu (L) 85                       Glu (E) or Asn (N)
      <br/>
      --      Asp (D) 69                       Lys (K) or Arg (R)
      <br/>
      --      Asn (N) 70                       Ala (A) or Glu (E)
      <br/>
      --      His (H) 9                        Ala (A) or Asp (D)
      <br/>
      --      Asn (N) 63                       Lys (K) or Arg (R)
      <br/>
      --      Thr (T) 34                       Gln (Q) or Lys (K)
    </p>
    <p num="115">
      It is not expected that every candidate substitution listed will result in the production of M-CSF agonists or antagonists (see Example 12 below).
      <br/>
      Rather they represent a non-exclusive list of candidates likely to result in the production of agonists or antagonists based on the selection criteria set forth above.
      <br/>
      It should also be noted that even if a variant does not act as an agonist or antagonist when compared with native M-CSF, the variant is still useful for conventional uses of the ligand (if it retains the same activity as the ligand) or as for example, a diagnostic reagent.
    </p>
    <p num="116">EXAMPLE 10</p>
    <p num="117">Preparation of H9A, H15A M-CSF Muteins</p>
    <p num="118">
      A variety of M-CSF muteins with altered solvent-accessible residues from regions of the M-CSF mature N terminus and helices A, C, and D were constructed using techniques known in the art.
      <br/>
      For example, two histidines in the N-terminal/A helix region were changed to alanine through site-directed mutagenesis of a truncated form of M-CSF ALPHA  (encoded by pLCSF158A).
      <br/>
      Involvement of one of three M-CSF histidine residues in M-CSF receptor interaction was implicated by our observation that diethylpyrocarbonate (DEPC) modification of histidines in M-CSF at a 1:100 DEPC:histidine ratio (as described in Meth. in Enzymol. 47:431 (1977)) significantly reduced bioactivity.
    </p>
    <p num="119">
      Plasmid DNA pLCSF158A was prepared from the E. coli strain HW22 carrying the plasmid pLCSF158A (U.S. Pat. No. 4,929,700, Example 6, "E. coli strain HW22 transformed with pJN653 containing the asp59 SCSF/N DELTA 3C DELTA 158 gene") The strain was grown in 350 ml R2 media (2 *  Luria Broth containing 1% sodium chloride and no glucose, J. Bact., 74:461 (1957)) containing 50 micrograms/ml ampicillin at 30 (degree)  C. with shaking overnight.
      <br/>
      Plasmid DNA was prepared from the cells using a Qiagen-tip 100 column according to the manufacturer's directions.
    </p>
    <p num="120">
      Twenty micrograms of pLCSF158A DNA were digested with 66 units of HindIII and 66 units of StuI at 37 (degree)  C. for 3 hr. 20 min. in 200 microliters 1 *  New England Biolabs NEBuffer 2 (New England Biolabs, Beverly, Mass.).
      <br/>
      The DNA was extracted with phenol and chloroform, then ethanol precipitated.
      <br/>
      The DNA was treated with one unit of Calf Intestinal Alkaline Phosphatase in 100 microliters of 1 *  Dephosphorylation Buffer, supplied by Boehringer Mannheim (Indianapolis, Ind.), at 37 (degree)  C. for 30 min.
      <br/>
      An additional unit of Calf Intestinal Alkaline Phosphatase was added to the reaction and incubation was continued at 50 (degree)  C. for 1 hr.
    </p>
    <p num="121">
      The resulting DNA was then run on a 1% FMC Bioproducts (Rockland, Me.) Sea KEM.RTM. GTG.RTM. agarose gel.
      <br/>
      The 5.7 kb pLCSF158A fragment was cut from the gel and purified on Qiagen (Chatsworth, Calif.) Qiaex beads according to the manufacturer's directions.
    </p>
    <p num="122">
      Polymerase chain reaction (PCR) was then performed and a PCR product was produced mat contained a mutagenized M-CSF sequence in which histidines 9 and 15 (counting from the mature N-terminus) were altered to alanine (generating an H9A, H15A PCR fragment).
      <br/>
      The 5' portion of the M-CSF gene was amplified from the plasmid pLCSF158A in a PCR reaction using the primers LF73 and LF74.
      <br/>
      Details of PCR are provided by Mullis, K. et al., U.S. Pat. No. 4,683,202; Ehrlich, H., U.S. Pat. No. 4,582,788; Saiki et al., U.S. Pat. No. 4,683,195; Mullis, K. B., Cold Spring Harbor Symp.
      <br/>
      Quant. Biol. 51:263-273 (1986); Saiki et al., Bio/Technology 3:1008-10012 (1985); and Mullis, K. B. et al., Meth. Enzymol 155:335-350 (1987), all of which are incorporated herein by reference.
      <br/>
      The sequences of these primers are:
    </p>
    <p num="123">
      LF73
      <br/>
      5'-AGGTGTCTCATAGAAAGTTCGGACGCAGGCCTTGTCATGCTCTTCATAATCCTTGG-3'  (SEQ ID NO. 1)
    </p>
    <p num="124">
      LF74
      <br/>
      5'-CAGGAGAAAGCTTATGTCTGAATATTGTAGCGCCATGATTGGGAGTGGAGCCCTGCAG-3'  (SEQ D NO. 2)
    </p>
    <p num="125">The expected PCR product was designed to include 337 bp of pLCSF158A sequence, with the HindIII and StuI sites located at each end of the product for cloning, and the histidine codons for His 9 and His 15, CAC, mutated to an alanine codons, GCC.</p>
    <p num="126">
      This product was amplified in four separate PCR reactions each containing 100 ng of pLCSF158A DNA, 50 pmoles LF73, 50 pmoles LF74, 37.5  MU M dNTPS, 5% glycerol, 1 *  Perkin Elmer Cetus PCR Buffer, and 2.5 units of Perkin Elmer Cetus AmpliTaq.RTM. DNA Polymerase in a 100 microliter volume.
      <br/>
      The amplification was carried out in a Perkin Elmer Cetus DNA thermocycler.
      <br/>
      Before adding the AmpliTaq.RTM., the reactions were brought to 95 (degree)  C. The amplification was carried out for 25 cycles ramping to a denaturation temperature of 95 (degree)  C. in 1 sec., denaturing at 95 (degree)  C. for 1 min.; ramping to an annealing temperature of 68 (degree)  C. in 1 sec., annealing at 68 (degree)  C. 1 min.; ramping to an extension temperature of 72 (degree)  C. in 30 sec., extending at 72 (degree)  C. 1 min., 30 sec. Final extension was carried out at 72 (degree)  C. for 10 min.
    </p>
    <p num="127">
      Five microliters of each reaction were run on a 3% agarose gel (1.5% FMC Bioproducts SeaKem.RTM. GTG.RTM. agarose, 1.5% FMC Bioproducts NuSeive.RTM. GTG.RTM. agarose in Tris-Borate buffer) (FMC Bioproducts, Rockland, Me.).
      <br/>
      Gels were then stained with ethidium bromide.
      <br/>
      For each reaction, a major band was visible at approximately 337 bp.
    </p>
    <p num="128">
      The four reactions were pooled, extracted with phenol and chloroform, precipitated with ethanol, resuspended and digested with 250 units of StuI in a final volume of 500 microliters 1 *  NEBuffer 2 at 37 (degree)  C. for 2 hr., 500 units of HindIII were added to the reaction, the volume increased to 1 ml in 1 *  NEBuffer 2 and digestion was continued at 37 (degree)  C. for an additional 2.5 hr. The DNA was electrophoresed on a 3% agarose gel.
      <br/>
      The 300 bp digested product was cut from the gel and purified on Qiagen Qiaex beads according to the manufacturer's directions.
    </p>
    <p num="129">
      Approximately 68 ng of the HindIII/StuI digested PCR product was then ligated to approximately 28 ng of the 5.7 kb HindIII/StuI digested pLCSF158A vector DNA at an insert-to-vector ratio of approximately 5:1.
      <br/>
      Ligation was carried out with 1 unit of Boehringer Mannheim T4 DNA ligase in 1 *  ligation buffer, supplied by the manufacturer, in a 20-microliter volume at 16 (degree)  C. overnight.
      <br/>
      As a control 28 ng of the 5.7 kb HindIII/StuI digested pLCSF158A vector DNA was ligated to itself under the same conditions with no insert present.
    </p>
    <p num="130">
      Half of each ligation mixture was used to transform competent E. coli DG116 (ATCC-53606) cells using a protocol similar to the calcium chloride. procedure described in Molecular Cloning a Laboratory Manual Maniatis et al., Cold Spring Harbor Laboratory (1982).
      <br/>
      Transformed cells were allowed to express at 30 (degree)  C. with no selection for 90 min., plated on R2-4 (10 g tryptone, 5 g yeast extract, 5 g NaCl, 2 drops antifoam A, 4 ml 50% glucose and 15 g agar in 1 liter) plates containing 50 micrograms/ml ampicillin.
      <br/>
      The plates were incubated at room temperature 72 hr.
      <br/>
      One fourth of each transformation was plated.
      <br/>
      For the ligation containing the insert, 66 ampicillin resistant colonies appeared on the plates.
      <br/>
      For the ligation with no insert, no colonies appeared.
    </p>
    <p num="131">
      One of these colonies, designated strain TAF172-2, was picked and cultured in 350 ml R2 broth with 50 micrograms/ml ampicillin at 30 (degree)  C. with shaking overnight.
      <br/>
      A frozen stock in 40% glycerol was made from this culture and stored at -70 (degree)  C. DNA was isolated from the culture using Qiagen-tip 100 columns as described above.
    </p>
    <p num="132">The purified DNA, pTAF172-2, was sequenced using the di-deoxy method and shown to contain the sequence of pLCSF158A coding for M-CSF N DELTA 3C DELTA 158 with His 9 and His 15 mutated to encode Ala.</p>
    <p num="133">The M-CSF mutein N DELTA 3C DELTA 158 H9A, H15A encoded by pTAF172-2 was expressed, purified, refolded to form dimeric protein and assayed essentially as described in U.S. Pat. No. 4,929,700 Example 5, using 8M urea as a denaturant and in the DEAE purification step.</p>
    <p num="134">
      The N-terminal sequence of the purified mutein was determined through 20 cycles, using a standard automated Edman degradation method, and shown to be identical to that of the parental N DELTA 3C DELTA 158 M-CSF ALPHA  reference protein except that His 9 and His 15 had been altered to Ala.
      <br/>
      Protein concentration was determined using A280 and an extinction co-efficient of 0.68.
    </p>
    <p num="135">
      The purified mutein dimers were subjected to bioassay using NFS-60 cells which is an M-CSF dependent cell line which forms colonies in the presence of active M-CSF.
      <br/>
      Standards and purified mutein samples were serially diluted 1:2 in RPMI media (10% fetal bovine serum) in a 50 microliter volume in 96-well microtiter plates. 50 microliters NFS-60 cells (ATCC NO. CRL 1838), maintained in 4000 U/ml M-CSF, washed 2 * , and diluted to a concentration of 1 * 105 cell/ml, were added to each sample well.
      <br/>
      Plates were incubated at 37 (degree)  C., 5% CO2 for 44 h. 5 mg/ml MTT dye was added to each sample and incubation continued for 4h. 20% SDS was added to each sample.
      <br/>
      The plates were wrapped in foil and left overnight.
      <br/>
      The absorbance of each sample was read at 570 nm and compared to a standard of known M-CSF concentration.
      <br/>
      The H9A, H15A mutein showed a specific activity of 7.6 * 103 U/mg compared to 6.9 * 107 U/mg for the parental M-CSF N DELTA 3C DELTA 158 reference in the same assay.
      <br/>
      This represents a nearly 10,000 fold reduction in biological activity for the mutein.
      <br/>
      The same M-CSF mutein preparation was shown to have greatly decreased M-CSF receptor-binding ability using the NFS-60 receptor competition assay described in this example.
      <br/>
      Because the H9A, H15A M-CSF mutein was otherwise not significantly different from the parental M-CSF ALPHA , including crystallizability and space group (see Example 12) we believe the decrease in, biological activity is not due to gross deformation of structure but reflects an alteration in important M-CSF receptor contacts.
    </p>
    <p num="136">
      Using essentially the same methodology, two M-CSF muteins contacting singly substituted histidines at residues 9 and 15 were generated (e.g. H9AL and H15A).
      <br/>
      The H9A construct utilized LF80:
      <br/>
      5'-CAGGAGAAAGCTTATGTCTGAATATTGTAGCGCCATGATTGGGAGTGGACACCTGCAG-3'  (SEQ ID NO 3);
    </p>
    <p num="137">
      and LF73 (described in this example) as the PCR primers.
      <br/>
      The H15A construct utilized LP81:
      <br/>
      5'-CAGGAGAAAGCTTATGTCTGAATATTGTAGCCACATGATTGGGAGTGGAGCCCTGCAG-3'  (SEQ ID NO. 4);
    </p>
    <p num="138">
      and LF 73 (described in this example) as PCR primers.
      <br/>
      Biological assay of the purified muteins immediately following the refolding step described above showed approximate biological specific activities as follows: 4 * 106 U/mg for H9A and less than 3 * 103 U/mg for H15A, in an assay which the parental ML-CSF construct displayed 8 * 107 U/mg.
      <br/>
      This information, combined with that described above, suggests that H15A as well as possible H9A represents contacts that are important for M-CSF receptor binding.
      <br/>
      Nearby solvent accessible residues such as Y6 and S13 (see also Table 1) may also represent M-CSF receptor contact residues.
      <br/>
      Non-proteinaceous mimics of the side chains of H9, H15, and nearby solvent accessible side chains may represent M-CSF agonists or antagonists.
      <br/>
      Such residues should be left unchanged in M-CSF mutein constructs designed to retain full M-CSF receptor binding but to have M-CSF antagonist properties because they lack significant M-CSF bioactivity.
      <br/>
      Homodimers of muteins that retain full receptor-binding ability and display significantly reduced bioactivity should represent M-CSF antagonists. M-CSF muteins that are greatly decreased in both M-CSF bioactivity and receptor binding ability (such as H15A) may generally be useful in M-CSF immunoassay applications and might represent useful therapeutic agents for patients having auto-antibodies to M-CSF.
    </p>
    <p num="139">EXAMPLE 11</p>
    <p num="140">Preparation of Q20A, V78K M-CSF Muteins</p>
    <p num="141">Using essentially the same methodology described in Example 10, a double mutant of M-CSF (Q20A, V78K) was constructed to test the importance of solvent accessible residues in the central portion of helices A and C. The followings PCR primers were used.</p>
    <p num="142">
      LF63
      <br/>
      5'-AGGAGAAAGCTTATGTCTGAATATTGTAGCCACATGATTGGGAGTGGACACCTGCAGT CTCTGGCTCGGCTG-3'  (SEQ ED NO. 5)
    </p>
    <p num="143">
      LF64
      <br/>
      5'-GGACGCAGGCCTTTGTCATGCTCTTCATAATCCTTGGTGAAGCAGCTCTTCAGCCTCAA AGAGAGTTCCTGCAGCTGTTTAATGGC-3'  (SEQ ID NO. 6)
    </p>
    <p num="144">
      The resulting mutein was expressed, refolded, purified, and assayed as described in Example 8.
      <br/>
      The specific biological activity was 1.4 * 107 U/mg, approximately 8-10 fold lower than that of the parental M-CSF ALPHA  reference standard.
      <br/>
      The receptor binding activity of this mutein was also decreased.
    </p>
    <p num="145">
      This result again supports the prediction of over crystallographic study of truncated M-CSF ALPHA  which concluded that important M-CSF receptor contact residues exist among the solvent accessible residues in helices A and/or C and/or D. Certain of these mutations will, as we have shown, have lower biological activity and lower M-CSF receptor-binding ability.
      <br/>
      Some may have lower biological activity without a decrease in receptor-binding ability.
      <br/>
      Some may have increased biologicals activity and receptor binding ability, and some may have no affect on either.
    </p>
    <p num="146">
      Two examples of the latter are Q17A, R21A (produced using PCR primers LF72:
      <br/>
      5'-TTGTAGCCACATGATTGGGAGTGGACACCTGGCGTCTCTGCAGGCGCTGATTGAC-3'
    </p>
    <p num="147">and</p>
    <p num="148">
      LF73 (described in Example 9) and E115A, N119A (produced using LF75:
      <br/>
      5'-CATGACAAGGCCTGCGTCCGAACMCTATGAGACACCTTCCCAGTTGCTGGCGAAGC TCAAGGCTGTCTTMAATG-3'  (SEQ ID NO. 7);
    </p>
    <p num="149">and</p>
    <p num="150">
      LF79
      <br/>
      5'-GGATCAGGATCCCTCGGACTGCCTCTC-3'  (SEQ ID NO. 8)).
    </p>
    <p num="151">
      Both of these constructs changed side chain properties of solvent-accessible amino) acids in the areas of interest but did not affect biological specific activity, compared to the parental reference molecule.
      <br/>
      These results indicate that residues Q17, R21, E115, and N119 do not need to be altered in muteins designed to have M-CSF agonist or antagonist activity.
      <br/>
      In fact, to minimize the likelihood of antibody formation to potentially administered M-CSF-based proteinaceous drugs, it is desirable to retain the solvent-accessible parental M-CSF residues (to resemble the native molecule) whenever possible.
    </p>
    <p num="152">
      The retained activity of the muteins including changes at Q17, R21, E115, and N119 does not rule out large affects on activity contributed by nearby residues (such as H15).
      <br/>
      In fact, the regions we have altered are predicted by the crystal structure to be important for receptor binding and/or signaling.
      <br/>
      Antagonistic M-CSF muteins may require use of multiple residue changes per mutein or use of heterodimeric molecules containing one or more mutations in each polypeptide chain, since M-CSF residues important in receptor signaling are believed to be composed of discontinuous regions of M-CSF.
    </p>
    <p num="153">EXAMPLE 12</p>
    <p num="154">Formation of M-CSF Heterodimers Having Decreased Receptor-Binding Ability and/or Decreased Biological Specific Activity</p>
    <p num="155">
      M-CSF can be folded in vitro to generate fully active heterodimers, as shown in Example 8.
      <br/>
      By making heterodimers of M-CSF which incorporate M-CSF muteins with altered M-CSF signaling ability, it should be possible to generate antagonists of M-CSF useful for treatment of patients with M-CSF mediated diseases.
      <br/>
      To generate a heterodimer containing one subunit of M-CSF ALPHA  N DELTA 3C DELTA 158 H9A, H15A and one subunit of M-CSF BETA  N DELTA 3C DELTA 221 C157S, C159S, each mutein was expressed in E. coli and purified separately by DEAE Sepharose under denaturing and reducing conditions as described in Example 8.
      <br/>
      The two muteins subunits were mixed together prior to refolding to generate a solution containing a final mutein molar ratio of 1:1, then this solution was diluted to 0.2 mg/ml with refolding buffer as described in Example 8.
      <br/>
      Following refolding, the heterodimeric molecule was separated from the homodimers by two consecutive passes over a Phenyl TSK-5-PW HPLC column as described in Example 8.
      <br/>
      No contaminants were detected when the purified heterodimer preparation was examined by non-reduced SDS-PAGE or size exclusion HPLC using a BioSil SEC250 column (BioRad).
    </p>
    <p num="156">
      The purified heterodimer was submitted to the NFS60 cell based bioassay described in Example 8.
      <br/>
      The calculated specific activity was 2.9 * 106 U/mg which correlated to a 35-fold reduction as compared to the activity of the parental M-CSF heterodimer described in Example 10.
      <br/>
      The relative binding affinity to cell surface M-CSF receptor was measured by radioligand displacement in which the displacement of 125 I-M-CSF from an M-CSF receptor by an M-CSF mutein was measured using methods well known in the art.
      <br/>
      In brief, the following were added in a final volume of 100  MU l in each well of a 96-well cell culture plate: approximately 80,000 cpm of purified recombinant human M-CSF labeled with 125 I (using Iodobeads as described by the manufacturer, Pierce, Rockford, Ill.), 300,000 NFS-60 cells that had been washed and then grown for 18 hours in growth medium minus the normal maintenance level of M-CSF, plus unlabeled M-CSF that had been serially diluted in the same medium.
      <br/>
      The plates were incubated at 4 (degree)  C. for 20 hours and the cells were collected on glass-fiber filters.
      <br/>
      Maximum binding was measured in the absence of unlabeled M-CSF and non-specific binding was measured in the presence of 1000-fold greater concentration of unlabeled M-CSF (compared to labeled M-CSF).
      <br/>
      The concentration of M-CSF required to inhibit 50% of the labeled M-CSF binding to the cells (IC50) was used to determine differences in affinity.
      <br/>
      Results are expressed as percent displacement of radioactive M-CSF versus mutein concentration (FIG. 7).
      <br/>
      The IC50 of the heterodimer (FIG. 7 closed squares) was reduced 30-fold to about 500 pM as compared to an IC50 of about 17 pM for M-CSF ALPHA  N DELTA 3C DELTA 158 (158) (FIG. 7 closed circles).
      <br/>
      The similarity between the reduction in specific activity and receptor affinity of the heterodimer indicates that the reduction in bioactivity was due to decreased receptor-binding ability.
      <br/>
      Similarly, the binding affinities of the Q20A, V78KF (FIG. 7 open circles) and -H9A, H15A (open squares) muteins were also measured in this radioligand displacement assay.
      <br/>
      The Q20A, V78K mutein had an IC50 of about 100 pM and the -H9A, H15A mutein has an IC50 of about 1  MU M, correlating to decreased binding affinities of 5-fold and 50,000-fold, respectively.
      <br/>
      For each mutein, the reduction in receptor affinity was similar to the reduction in specific activity, again indicating that the reduction in bioactivity was due to reduced receptor-binding ability.
    </p>
    <p num="157">EXAMPLE 13</p>
    <p num="158">Crystallization and Characterization Of M-CSF H9A, H15A Muteins</p>
    <p num="159">
      The H9A, H15A mutein described in Example 10 was crystallized using the hanging drop method described in Examples 1 and 2 using the following buffer conditions: 30% polyethylene glycol 4000; 100 mM Li2 SO4 ; and 100 mM Tris pH 8.5. The crystals produced under these conditions were rhombohedral prisms having dimensions of 0.7 mm * 0.2 mm * 0.2 mm. X-ray crystallographic analysis using precession photographs showed crystals in the P21 21 21 space group with cell dimensions of a=33.99, b=65.37, c=159.90, d=90, e=90, and f=90 angstroms and diffract to a nominal resolution of 3 angstroms.
      <br/>
      These physical properties are essentially the same as those observed for the parental N DELTA 3C DELTA 158 M-CSF ALPHA  molecule and suggests that the biological effects of the H9A, H15A alterations are not the consequence of gross global alterations in M-CSF structure, but rather are the result of altered side chains that are important in interacting with the M-CSF receptor.
      <br/>
      Alteration of those histidine side chains may have affected receptor binding by changing atoms that interact with, stabilize or facilitate receptor binding or changes in receptor conformation.
      <br/>
      Changes such as H15A may also have affected these functions by altering the position of the nearby side chain in M-CSF, most likely in the A and/or C helix regions.
    </p>
    <p num="160">The foregoing examples are presented by way of example and are not intended to limit the scope of the invention as set forth in the appended claims.</p>
    <p num="161">
      -- APPENDIX 1
      <br/>
      -- ATOM      10     CA     SER    4       63.753  80.590    222.385 1.00
      <br/>
      --  58.89
      <br/>
      -- ATOM      13     CA     GLU    5       64.883  77.664    219.972 1.00
      <br/>
      --  59.56
      <br/>
      -- ATOM      23     CA     TYR    6       62.285  76.840    217.324 1.00
      <br/>
      --  54.54
      <br/>
      -- ATOM      37     CA     CYS    7       63.509  80.109    215.834 1.00
      <br/>
      --  54.96
      <br/>
      -- ATOM      44     CA     SER    8       66.853  79.529    214.160 1.00
      <br/>
      --  54.41
      <br/>
      -- ATOM      52     CA     HIS    9       65.466  77.798    211.053 1.00
      <br/>
      --  55.11
      <br/>
      -- ATOM      65     CA     MET    10      61.857  78.767    211.073 1.00
      <br/>
      --  50.66
      <br/>
      -- ATOM      74     CA     ILE    11      62.173  80.905    207.970 1.00
      <br/>
      --  48.31
      <br/>
      -- ATOM      83     CA     GLY    12      63.487  78.618    205.354 1.00
      <br/>
      --  52.83
      <br/>
      -- ATOM      88     CA     SER    13      64.609  79.967    201.952 1.00
      <br/>
      --  53.13
      <br/>
      -- ATOM      96     CA     GLY    14      61.665  78.009    200.514 1.00
      <br/>
      --  46.05
      <br/>
      -- ATOM      101    CA     HIS    15      59.455  80.924    201.933 1.00
      <br/>
      --  40.25
      <br/>
      -- ATOM      114    CA     LEU    16      62.210  83.200    200.992 1.00
      <br/>
      --  41.58
      <br/>
      -- ATOM      123    CA     GLN    17      62.153  82.266    197.328 1.00
      <br/>
      --  46.17
      <br/>
      -- ATOM      135    CA     SER    18      58.378  81.868    197.227 1.00
      <br/>
      --  46.55
      <br/>
      -- ATOM      143    CA     LEU    19      58.280  85.544    198.199 1.00
      <br/>
      --  44.75
      <br/>
      -- ATOM      152    CA     GLN    20      60.814  86.044    195.458 1.00
      <br/>
      --  39.32
      <br/>
      -- ATOM      164    CA     ARG    21      58.457  84.718    192.736 1.00
      <br/>
      --  36.91
      <br/>
      -- ATOM      181    CA     LEU    22      55.610  86.694    194.252 1.00
      <br/>
      --  38.27
      <br/>
      -- ATOM      190    CA     ILE    23      57.676  89.822    193.465 1.00
      <br/>
      --  34.84
      <br/>
      -- ATOM      199    CA     ASP    24      58.677  88.274    190.086 1.00
      <br/>
      --  31.50
      <br/>
      -- ATOM      208    CA     SER    25      55.086  87.802    188.978 1.00
      <br/>
      --  31.73
      <br/>
      -- ATOM      216    CA     GLN    26      54.284  91.540    189.154 1.00
      <br/>
      --  33.24
      <br/>
      -- ATOM      228    CA     MET    27      53.961  93.634    186.082 1.00
      <br/>
      --  34.82
      <br/>
      -- ATOM      237    CA     GLU    28      56.227  96.566    186.089 1.00
      <br/>
      --  36.54
      <br/>
      -- ATOM      247    CA     THR    29      53.758  99.303    186.920 1.00
      <br/>
      --  44.80
      <br/>
      -- ATOM      256    CA     SER    30      54.590  102.747   188.323 1.00
      <br/>
      --  49.40
      <br/>
      -- ATOM      264    CA     CYS    31      51.427  103.423   190.046 1.00
      <br/>
      --  43.03
      <br/>
      -- ATOM      271    CA     GLN    32      52.166  104.336   193.613 1.00
      <br/>
      --  33.74
      <br/>
      -- ATOM      283    CA     ILE    33      50.430  102.961   196.634 1.00
      <br/>
      --  32.48
      <br/>
      -- ATOM      292    CA     THR    34      50.240  104.213   200.133 1.00
      <br/>
      --  38.94
      <br/>
      -- ATOM      301    CA     PHE    35      51.291  102.173   203.199 1.00
      <br/>
      --  39.16
      <br/>
      -- ATOM      313    CA     GLU    36      52.707  102.849   206.761 1.00
      <br/>
      --  32.09
      <br/>
      -- ATOM      323    CA     PHE    37      56.073  101.358   207.299 1.00
      <br/>
      --  25.78
      <br/>
      -- ATOM      335    CA     VAL    38      59.082  101.751   209.490 1.00
      <br/>
      --  34.46
      <br/>
      -- ATOM      343    CA     ASP    39      61.044  104.798   208.714 1.00
      <br/>
      --  44.03
      <br/>
      -- ATOM      352    CA     GLN    40      64.648  103.690   208.314 1.00
      <br/>
      --  54.20
      <br/>
      -- ATOM      364    CA     GLU    41      65.924  107.142   209.332 1.00
      <br/>
      --  52.01
      <br/>
      -- ATOM      374    CA     GLN    42      63.934  107.629   212.631 1.00
      <br/>
      --  44.26
      <br/>
      -- ATOM      386    CA     LEU    43      64.770  104.161   213.955 1.00
      <br/>
      --  45.54
      <br/>
      -- ATOM      395    CA     ALA    44      68.126  102.952   212.789 1.00
      <br/>
      --  51.53
      <br/>
      -- ATOM      401    CA     ASP    45      69.175  100.197   215.232 1.00
      <br/>
      --  47.92
      <br/>
      -- ATOM      410    CA     PRO    46      68.861  97.054    213.098 1.00
      <br/>
      --  45.27
      <br/>
      -- ATOM      417    CA     VAL    47      67.352  94.587    215.613 1.00
      <br/>
      --  39.92
      <br/>
      -- ATOM      425    CA     CYS    48      64.862  97.220    216.692 1.00
      <br/>
      --  36.44
      <br/>
      -- ATOM      432    CA     TYR    49      64.089  98.158    213.105 1.00
      <br/>
      --  37.39
      <br/>
      -- ATOM      446    CA     LEU    50      63.436  94.474    212.189 1.00
      <br/>
      --  36.15
      <br/>
      -- ATOM      455    CA     LYS    51      61.603  94.029    215.472 1.00
      <br/>
      --  38.66
      <br/>
      -- ATOM      468    CA     LYS    52      59.322  96.862    214.367 1.00
      <br/>
      --  41.72
      <br/>
      -- ATOM      481    CA     ALA    53      59.229  96.177    210.534 1.00
      <br/>
      --  35.81
      <br/>
      -- ATOM      487    CA     PHE    54      58.096  92.701    211.432 1.00
      <br/>
      --  40.82
      <br/>
      -- ATOM      499    CA     LEU    55      55.236  93.733    213.614 1.00
      <br/>
      --  42.59
      <br/>
      -- ATOM      508    CA     LEU    56      54.205  95.869    210.697 1.00
      <br/>
      --  44.24
      <br/>
      -- ATOM      517    CA     VAL    57      54.596  93.257    207.992 1.00
      <br/>
      --  35.10
      <br/>
      -- ATOM      525    CA     GLN    58      51.646  91.431    209.628 1.00
      <br/>
      --  39.91
      <br/>
      -- ATOM      537    CA     ASP    59      49.277  94.254    208.663 1.00
      <br/>
      --  39.60
      <br/>
      -- ATOM      546    CA     ILE    60      50.755  94.729    205.185 1.00
      <br/>
      --  37.05
      <br/>
      -- ATOM      555    CA     MET    61      50.303  90.932    204.676 1.00
      <br/>
      --  33.86
      <br/>
      -- ATOM      564    CA     GLU    62      46.766  90.931    206.028 1.00
      <br/>
      --  48.10
      <br/>
      -- ATOM      574    CA     ASP    63      45.602  94.198    204.286 1.00
      <br/>
      --  49.51
      <br/>
      -- ATOM      583    CA     THR    64      47.659  95.244    201.187 1.00
      <br/>
      --  42.65
      <br/>
      -- ATOM      592    CA     MET    65      49.106  92.155    199.603 1.00
      <br/>
      --  37.90
      <br/>
      -- ATOM      601    CA     ARG    66      45.646  91.249    198.376 1.00
      <br/>
      --  39.50
      <br/>
      -- ATOM      618    CA     PHE    67      45.516  88.245    195.824 1.00
      <br/>
      --  35.13
      <br/>
      -- ATOM      630    CA     ARG    68      42.655  86.013    194.326 1.00
      <br/>
      --  44.68
      <br/>
      -- ATOM      647    CA     ASP    69      41.727  83.454    196.865 1.00
      <br/>
      --  47.42
      <br/>
      -- ATOM      656    CA     ASN    70      43.117  80.057    195.984 1.00
      <br/>
      --  44.47
      <br/>
      -- ATOM      667    CA     THR    71      45.873  81.088    193.518 1.00
      <br/>
      --  34.80
      <br/>
      -- ATOM      676    CA     PRO    72      49.607  80.251    194.114 1.00
      <br/>
      --  29.78
      <br/>
      -- ATOM      683    CA     ASN    73      50.307  83.745    195.418 1.00
      <br/>
      --  28.47
      <br/>
      -- ATOM      694    CA     ALA    74      47.469  83.922    197.953 1.00
      <br/>
      --  23.24
      <br/>
      -- ATOM      700    CA     ILE    75      48.690  80.431    199.144 1.00
      <br/>
      --  22.87
      <br/>
      -- ATOM      709    CA     ALA    76      52.212  81.892    199.669 1.00
      <br/>
      --  29.47
      <br/>
      -- ATOM      715    CA     ILE    77      50.816  84.796    201.668 1.00
      <br/>
      --  37.21
      <br/>
      -- ATOM      724    CA     VAL    78      48.902  82.158    203.857 1.00
      <br/>
      --  33.69
      <br/>
      -- ATOM      732    CA     GLN    79      52.207  80.382    204.466 1.00
      <br/>
      --  33.36
      <br/>
      -- ATOM      744    CA     LEU    80      54.040  83.518    205.449 1.00
      <br/>
      --  32.55
      <br/>
      -- ATOM      753    CA     GLN    81      51.152  84.517    207.743 1.00
      <br/>
      --  35.07
      <br/>
      -- ATOM      765    CA     GLU    82      51.541  81.115    209.443 1.00
      <br/>
      --  37.26
      <br/>
      -- ATOM      775    CA     LEU    83      55.367  81.348    209.619 1.00
      <br/>
      --  35.10
      <br/>
      -- ATOM      784    CA     SER    84      54.960  84.840    211.066 1.00
      <br/>
      --  39.64
      <br/>
      -- ATOM      792    CA     LEU    85      52.608  83.541    213.704 1.00
      <br/>
      --  42.55
      <br/>
      -- ATOM      801    CA     ARG    86      54.984  80.903    215.121 1.00
      <br/>
      --  42.96
      <br/>
      -- ATOM      818    CA     LEU    87      57.916  83.317    214.670 1.00
      <br/>
      --  45.11
      <br/>
      -- ATOM      827    CA     LYS    88      56.504  85.876    217.138 1.00
      <br/>
      --  50.71
      <br/>
      -- ATOM      840    CA     SER    89      57.621  83.610    219.825 1.00
      <br/>
      --  54.58
      <br/>
      -- ATOM      848    CA     CYS    90      61.211  84.524    219.014 1.00
      <br/>
      --  46.79
      <br/>
      -- ATOM      855    CA     PHE    91      60.235  88.070    219.743 1.00
      <br/>
      --  46.37
      <br/>
      -- ATOM      867    CA     THR    92      59.619  89.812    223.026 1.00
      <br/>
      --  52.01
      <br/>
      -- ATOM      876    CA     ALA    93      56.916  92.445    223.523 1.00
      <br/>
      --  56.09
      <br/>
      -- ATOM      882    CA     ASP    94      57.914  96.123    223.998 1.00
      <br/>
      --  59.35
      <br/>
      -- ATOM      891    CA     TYR    95      55.685  99.100    225.194 1.00
      <br/>
      --  66.22
      <br/>
      -- ATOM      905    CA     GLU    96      52.401  100.066   223.612 1.00
      <br/>
      --  65.51
      <br/>
      -- ATOM      915    CA     GLU    97      53.343  103.890   223.182 1.00
      <br/>
      --  62.60
      <br/>
      -- ATOM      925    CA     HIS    98      56.046  102.712   220.836 1.00
      <br/>
      --  58.47
      <br/>
      -- ATOM      938    CA     ASP    99      53.422  100.733   218.887 1.00
      <br/>
      --  59.97
      <br/>
      -- ATOM      947    CA     LYS    100     52.950  103.470   216.162 1.00
      <br/>
      --  57.00
      <br/>
      -- ATOM      960    CA     ALA    101     56.259  105.270   216.975 1.00
      <br/>
      --  48.82
      <br/>
      -- ATOM      966    CA     CYS    102     58.861  105.450   214.154 1.00
      <br/>
      --  42.41
      <br/>
      -- ATOM      973    CA     VAL    103     56.175  104.773   211.621 1.00
      <br/>
      --  33.87
      <br/>
      -- ATOM      981    CA     ARG    104     55.993  106.851   208.456 1.00
      <br/>
      --  42.76
      <br/>
      -- ATOM      998    CA     THR    105     53.577  106.853   205.501 1.00
      <br/>
      --  38.00
      <br/>
      -- ATOM      1007   CA     PHE    106     54.931  105.944   202.136 1.00
      <br/>
      --  33.48
      <br/>
      -- ATOM      1019   CA     TYR    107     53.853  106.546   198.455 1.00
      <br/>
      --  34.28
      <br/>
      -- ATOM      1033   CA     GLU    108     55.765  103.906   196.543 1.00
      <br/>
      --  33.88
      <br/>
      -- ATOM      1043   CA     THR    109     55.266  101.309   193.854 1.00
      <br/>
      --  36.94
      <br/>
      -- ATOM      1052   CA     PRO    110     53.745  97.857    194.657 1.00
      <br/>
      --  29.84
      <br/>
      -- ATOM      1059   CA     LEU    111     57.132  96.374    193.761 1.00
      <br/>
      --  35.66
      <br/>
      -- ATOM      1068   CA     GLN    112     58.991  98.756    196.160 1.00
      <br/>
      --  33.48
      <br/>
      -- ATOM      1080   CA     LEU    113     56.612  97.691    198.912 1.00
      <br/>
      --  24.26
      <br/>
      -- ATOM      1089   CA     LEU    114     57.253  93.932    198.091 1.00
      <br/>
      --  30.75
      <br/>
      -- ATOM      1098   CA     GLU    115     61.063  94.385    197.984 1.00
      <br/>
      --  39.68
      <br/>
      -- ATOM      1108   CA     LYS    116     60.805  95.824    201.526 1.00
      <br/>
      --  39.24
      <br/>
      -- ATOM      1121   CA     VAL    117     58.669  92.840    202.743 1.00
      <br/>
      --  32.46
      <br/>
      -- ATOM      1129   CA     LYS    118     61.312  90.620    201.111 1.00
      <br/>
      --  37.34
      <br/>
      -- ATOM      1142   CA     ASN    119     64.231  92.316    202.959 1.00
      <br/>
      --  39.46
      <br/>
      -- ATOM      1153   CA     VAL    120     62.470  92.033    206.370 1.00
      <br/>
      --  32.07
      <br/>
      -- ATOM      1161   CA     PHE    121     61.935  88.268    206.034 1.00
      <br/>
      --  26.35
      <br/>
      -- ATOM      1173   CA     ASN    122     65.404  88.049    204.416 1.00
      <br/>
      --  36.04
      <br/>
      -- ATOM      1184   CA     GLU    123     67.372  89.816    207.138 1.00
      <br/>
      --  40.82
      <br/>
      -- ATOM      1194   CA     THR    124     65.331  88.435    210.122 1.00
      <br/>
      --  41.72
      <br/>
      -- ATOM      1203   CA     LYS    125     66.456  85.000    208.648 1.00
      <br/>
      --  43.07
      <br/>
      -- ATOM      1216   CA     ASN    126     70.010  86.339    208.179 1.00
      <br/>
      --  48.89
      <br/>
      -- ATOM      1227   CA     LEU    127     70.000  87.300    211.903 1.00
      <br/>
      --  47.97
      <br/>
      -- ATOM      1236   CA     LEU    128     68.315  84.194    213.435 1.00
      <br/>
      --  47.21
      <br/>
      -- ATOM      1245   CA     ASP    129     71.086  82.134    211.864 1.00
      <br/>
      --  50.11
      <br/>
      -- ATOM      1254   CA     LYS    130     73.448  84.146    214.117 1.00
      <br/>
      --  52.04
      <br/>
      -- ATOM      1267   CA     ASP    131     71.442  84.303    217.451 1.00
      <br/>
      --  49.48
      <br/>
      -- ATOM      1276   CA     TRP    132     67.946  82.685    218.322 1.00
      <br/>
      --  53.33
      <br/>
      -- ATOM      1292   CA     ASN    133     67.568  85.178    221.086 1.00
      <br/>
      --  59.61
      <br/>
      -- ATOM      1303   CA     ILE    134     68.572  88.447    219.305 1.00
      <br/>
      --  49.82
      <br/>
      -- ATOM      1312   CA     PHE    135     64.945  89.516    219.045 1.00
      <br/>
      --  54.55
      <br/>
      -- ATOM      1324   CA     SER    136     64.745  89.689    222.796 1.00
      <br/>
      --  62.26
      <br/>
      -- ATOM      1332   CA     LYS    137     66.563  93.119    222.569 1.00
      <br/>
      --  54.38
      <br/>
      -- ATOM      1345   CA     ASN    138     64.785  95.734    224.504 1.00
      <br/>
      --  58.71
      <br/>
      -- ATOM      1356   CA     CYS    139     63.902  98.337    222.050 1.00
      <br/>
      --  51.21
      <br/>
      -- ATOM      1363   CA     ASN    140     61.704  100.578   224.157 1.00
      <br/>
      --  50.25
      <br/>
      -- ATOM      1374   CA     ASN    141     64.219  103.338   224.061 1.00
      <br/>
      --  58.30
      <br/>
      -- ATOM      1385   CA     SER    142     65.158  102.992   220.352 1.00
      <br/>
      --  52.18
      <br/>
      -- ATOM      1393   CA     PHE    143     61.498  103.434   219.645 1.00
      <br/>
      --  45.87
      <br/>
      -- ATOM      1405   CA     ALA    144     61.829  106.488   221.831 1.00
      <br/>
      --  47.49
      <br/>
      -- ATOM      1411   CA     GLU    145     64.873  108.022   220.050 1.00
      <br/>
      --  49.94
      <br/>
      -- ATOM      1421   CA     CYS    146     62.489  108.299   217.017 1.00
      <br/>
      --  53.65
      <br/>
      -- ATOM      1428   CA     SER    147     60.005  111.197   217.009 1.00
      <br/>
      --  57.45
      <br/>
      -- ATOM      1436   CA     SER    148     57.163  110.805   214.395 1.00
      <br/>
      --  59.53
      <br/>
      -- ATOM      1444   CA     ALA    149     54.284  108.658   214.945 1.00
      <br/>
      --  59.20
      <br/>
      -- ATOM      1450   CA     GLY    150     51.655  108.783   212.248 1.00
      <br/>
      --  61.95
      <br/>
      -- ATOM      1455   CA     HIS    151     48.764  106.945   210.680 1.00
      <br/>
      --  69.20
      <br/>
      -- ATOM      1468   CA     GLU    152     46.475  107.377   207.803 1.00
      <br/>
      --  76.61
      <br/>
      -- ATOM      1478   CA     ALA    153     45.813  106.188   204.264 1.00
      <br/>
      --  78.85
      <br/>
      -- ATOM      1492   CA     SER    404     43.875  81.916    155.536 1.00
      <br/>
      --  38.68
      <br/>
      -- ATOM      1495   CA     GLU    405     41.939  78.947    156.798 1.00
      <br/>
      --  43.57
      <br/>
      -- ATOM      1505   CA     TYR    406     44.549  78.204    159.422 1.00
      <br/>
      --  41.97
      <br/>
      -- ATOM      1519   CA     CYS    407     43.251  81.196    161.434 1.00
      <br/>
      --  36.99
      <br/>
      -- ATOM      1526   CA     SER    408     41.011  78.917    163.442 1.00
      <br/>
      --  34.02
      <br/>
      -- ATOM      1534   CA     HIS    409     43.988  77.122    165.021 1.00
      <br/>
      --  40.02
      <br/>
      -- ATOM      1547   CA     MET    410     46.155  79.994    165.895 1.00
      <br/>
      --  36.48
      <br/>
      -- ATOM      1556   CA     ILE    411     44.849  80.843    169.353 1.00
      <br/>
      --  37.88
      <br/>
      -- ATOM      1565   CA     GLY    412     44.508  77.692    171.141 1.00
      <br/>
      --  39.09
      <br/>
      -- ATOM      1570   CA     SER    413     43.275  77.480    174.756 1.00
      <br/>
      --  45.21
      <br/>
      -- ATOM      1578   CA     GLY    414     46.813  77.142    176.120 1.00
      <br/>
      --  41.00
      <br/>
      -- ATOM      1583   CA     HIS    415     47.238  80.801    175.208 1.00
      <br/>
      --  38.01
      <br/>
      -- ATOM      1596   CA     LEU    416     44.181  81.554    177.458 1.00
      <br/>
      --  39.12
      <br/>
      -- ATOM      1605   CA     GLN    417     45.501  79.575    180.501 1.00
      <br/>
      --  39.79
      <br/>
      -- ATOM      1617   CA     SER    418     48.547  81.846    180.317 1.00
      <br/>
      --  36.95
      <br/>
      -- ATOM      1625   CA     LEU    419     46.482  85.106    180.212 1.00
      <br/>
      --  33.42
      <br/>
      -- ATOM      1634   CA     GLN    420     44.564  83.708    183.162 1.00
      <br/>
      --  38.37
      <br/>
      -- ATOM      1646   CA     ARG    421     47.839  82.875    185.041 1.00
      <br/>
      --  41.95
      <br/>
      -- ATOM      1663   CA     LEU    422     49.151  86.514    184.405 1.00
      <br/>
      --  33.04
      <br/>
      -- ATOM      1672   CA     ILE    423     45.854  87.864    185.738 1.00
      <br/>
      --  25.14
      <br/>
      -- ATOM      1681   CA     ASP    424     45.824  85.549    188.861 1.00
      <br/>
      --  32.93
      <br/>
      -- ATOM      1690   CA     SER    425     49.394  86.494    189.904 1.00
      <br/>
      --  30.92
      <br/>
      -- ATOM      1698   CA     GLN    426     48.776  90.276    189.999 1.00
      <br/>
      --  29.47
      <br/>
      -- ATOM      1710   CA     MET    427     48.379  91.899    193.372 1.00
      <br/>
      --  31.04
      <br/>
      -- ATOM      1719   CA     GLU    428     44.978  93.418    193.655 1.00
      <br/>
      --  42.94
      <br/>
      -- ATOM      1729   CA     THR    429     45.965  96.999    194.423 1.00
      <br/>
      --  48.52
      <br/>
      -- ATOM      1738   CA     SER    430     43.656  99.720    193.224 1.00
      <br/>
      --  48.67
      <br/>
      -- ATOM      1746   CA     CYS    431     46.604  101.354   191.803 1.00
      <br/>
      --  52.34
      <br/>
      -- ATOM      1753   CA     GLN    432     45.813  102.789   188.396 1.00
      <br/>
      --  50.77
      <br/>
      -- ATOM      1765   CA     ILE    433     47.826  103.166   185.221 1.00
      <br/>
      --  51.17
      <br/>
      -- ATOM      1774   CA     THR    434     46.923  105.057   182.065 1.00
      <br/>
      --  52.62
      <br/>
      -- ATOM      1783   CA     PHE    435     46.641  103.293   178.672 1.00
      <br/>
      --  50.53
      <br/>
      -- ATOM      1795   CA     GLU    436     45.167  103.968   175.164 1.00
      <br/>
      --  50.56
      <br/>
      -- ATOM      1805   CA     PHE    437     42.643  101.271   174.193 1.00
      <br/>
      --  46.56
      <br/>
      -- ATOM      1817   CA     VAL    438     39.404  101.233   172.116 1.00
      <br/>
      --  52.14
      <br/>
      -- ATOM      1825   CA     ASP    439     36.342  103.107   173.476 1.00
      <br/>
      --  59.69
      <br/>
      -- ATOM      1834   CA     GLN    440     33.750  100.386   173.243 1.00
      <br/>
      --  63.82
      <br/>
      -- ATOM      1846   CA     GLU    441     30.764  102.682   173.229 1.00
      <br/>
      --  64.79
      <br/>
      -- ATOM      1856   CA     GLN    442     31.810  104.569   170.091 1.00
      <br/>
      --  59.01
      <br/>
      -- ATOM      1868   CA     LEU    443     32.994  101.521   168.139 1.00
      <br/>
      --  55.78
      <br/>
      -- ATOM      1877   CA     LYS    444     30.279  99.137    169.086 1.00
      <br/>
      --  54.82
      <br/>
      -- ATOM      1890   CA     ASP    445     30.862  96.668    166.093 1.00
      <br/>
      --  51.31
      <br/>
      -- ATOM      1899   CA     PRO    446     32.144  93.267    167.135 1.00
      <br/>
      --  47.34
      <br/>
      -- ATOM      1906   CA     VAL    447     34.363  92.592    164.111 1.00
      <br/>
      --  41.42
      <br/>
      -- ATOM      1914   CA     CYS    448     35.680  96.184    163.845 1.00
      <br/>
      --  39.44
      <br/>
      -- ATOM      1921   CA     TYR    449     36.273  96.949    167.607 1.00
      <br/>
      --  40.33
      <br/>
      -- ATOM      1935   CA     LEU    450     38.224  93.580    167.624 1.00
      <br/>
      --  30.87
      <br/>
      -- ATOM      1944   CA     LYS    451     39.989  94.664    164.462 1.00
      <br/>
      --  34.49
      <br/>
      -- ATOM      1957   CA     LYS    452     40.962  97.918    166.163 1.00
      <br/>
      --  35.38
      <br/>
      -- ATOM      1970   CA     ALA    453     41.503  96.317    169.572 1.00
      <br/>
      --  28.00
      <br/>
      -- ATOM      1976   CA     PHE    454     44.012  93.845    168.164 1.00
      <br/>
      --  32.56
      <br/>
      -- ATOM      1988   CA     LEU    455     46.236  96.653    166.861 1.00
      <br/>
      --  40.19
      <br/>
      -- ATOM      1997   CA     LEU    456     46.402  98.605    170.114 1.00
      <br/>
      --  42.45
      <br/>
      -- ATOM      2006   CA     VAL    457     46.966  95.358    172.060 1.00
      <br/>
      --  38.09
      <br/>
      -- ATOM      2014   CA     GLN    458     50.298  95.232    170.161 1.00
      <br/>
      --  48.02
      <br/>
      -- ATOM      2026   CA     ASP    459     51.630  98.529    171.587 1.00
      <br/>
      --  41.96
      <br/>
      -- ATOM      2035   CA     ILE    460     50.230  97.686    175.001 1.00
      <br/>
      --  25.82
      <br/>
      -- ATOM      2044   CA     MET    461     52.409  94.542    175.085 1.00
      <br/>
      --  33.69
      <br/>
      -- ATOM      2053   CA     GLU    462     55.702  96.253    173.969 1.00
      <br/>
      --  45.36
      <br/>
      -- ATOM      2063   CA     ASP    463     55.069  99.093    176.249 1.00
      <br/>
      --  48.41
      <br/>
      -- ATOM      2072   CA     THR    464     52.771  98.555    179.186 1.00
      <br/>
      --  41.63
      <br/>
      -- ATOM      2081   CA     MET    465     52.743  94.854    180.171 1.00
      <br/>
      --  42.05
      <br/>
      -- ATOM      2090   CA     ARG    466     56.333  94.928    181.338 1.00
      <br/>
      --  44.99
      <br/>
      -- ATOM      2107   CA     PHE    467     57.618  91.923    183.501 1.00
      <br/>
      --  38.72
      <br/>
      -- ATOM      2119   CA     ARG    468     61.258  90.894    184.513 1.00
      <br/>
      --  50.64
      <br/>
      -- ATOM      2136   CA     ASP    469     63.046  88.868    181.895 1.00
      <br/>
      --  53.46
      <br/>
      -- ATOM      2145   CA     ASN    470     62.896  85.096    181.832 1.00
      <br/>
      --  52.84
      <br/>
      -- ATOM      2156   CA     THR    471     60.211  84.798    184.479 1.00
      <br/>
      --  47.58
      <br/>
      -- ATOM      2165   CA     PRO    472     57.055  82.652    183.744 1.00
      <br/>
      --  46.82
      <br/>
      -- ATOM      2172   CA     ASN    473     54.971  85.777    183.172 1.00
      <br/>
      --  38.75
      <br/>
      -- ATOM      2183   CA     ALA    474     57.431  87.402    180.828 1.00
      <br/>
      --  37.27
      <br/>
      -- ATOM      2189   CA     ILE    475     57.795  84.219    178.807 1.00
      <br/>
      --  32.85
      <br/>
      -- ATOM      2198   CA     ALA    476     54.021  84.034    178.455 1.00
      <br/>
      --  27.98
      <br/>
      -- ATOM      2204   CA     ILE    477     53.844  87.522    176.756 1.00
      <br/>
      --  30.47
      <br/>
      -- ATOM      2213   CA     VAL    478     56.690  86.495    174.201 1.00
      <br/>
      --  30.40
      <br/>
      -- ATOM      2221   CA     GLN    479     54.381  83.711    173.325 1.00
      <br/>
      --  31.18
      <br/>
      -- ATOM      2233   CA     LEU    480     51.419  86.038    172.893 1.00
      <br/>
      --  27.44
      <br/>
      -- ATOM      2242   CA     GLN    481     53.392  88.551    170.821 1.00
      <br/>
      --  31.59
      <br/>
      -- ATOM      2254   CA     GLU    482     54.572  85.683    168.506 1.00
      <br/>
      --  29.90
      <br/>
      -- ATOM      2264   CA     LEU    483     50.900  84.532    168.340 1.00
      <br/>
      --  22.16
      <br/>
      -- ATOM      2273   CA     SER    484     50.077  88.156    167.451 1.00
      <br/>
      --  29.37
      <br/>
      -- ATOM      2281   CA     LEU    485     52.410  87.880    164.490 1.00
      <br/>
      --  32.70
      <br/>
      -- ATOM      2290   CA     ARG    486     50.865  84.572    163.229 1.00
      <br/>
      --  30.59
      <br/>
      -- ATOM      2307   CA     LEU    487     47.396  86.383    163.343 1.00
      <br/>
      --  31.02
      <br/>
      -- ATOM      2316   CA     LYS    488     48.292  89.399    161.352 1.00
      <br/>
      --  34.90
      <br/>
      -- ATOM      2329   CA     SER    489     47.728  87.397    158.200 1.00
      <br/>
      --  35.68
      <br/>
      -- ATOM      2337   CA     CYS    490     44.112  87.134    159.417 1.00
      <br/>
      --  35.03
      <br/>
      -- ATOM      2344   CA     PHE    491     43.520  90.786    159.602 1.00
      <br/>
      --  42.73
      <br/>
      -- ATOM      2356   CA     THR    492     43.145  93.174    156.663 1.00
      <br/>
      --  56.24
      <br/>
      -- ATOM      2365   CA     ALA    493     44.877  96.467    156.617 1.00
      <br/>
      --  57.56
      <br/>
      -- ATOM      2371   CA     ASP    494     42.318  99.142    157.302 1.00
      <br/>
      --  57.16
      <br/>
      -- ATOM      2380   CA     ALA    495     42.063  102.909   156.516 1.00
      <br/>
      --  62.14
      <br/>
      -- ATOM      2386   CA     GLU    496     45.542  104.198   157.805 1.00
      <br/>
      --  64.30
      <br/>
      -- ATOM      2396   CA     GLU    497     44.589  107.547   159.382 1.00
      <br/>
      --  70.67
      <br/>
      -- ATOM      2406   CA     HIS    498     41.577  105.660   160.752 1.00
      <br/>
      --  75.16
      <br/>
      -- ATOM      2419   CA     ASP    499     44.400  103.329   161.968 1.00
      <br/>
      --  72.11
      <br/>
      -- ATOM      2428   CA     LYS    500     44.773  105.712   164.874 1.00
      <br/>
      --  65.63
      <br/>
      -- ATOM      2441   CA     ALA    501     41.040  106.628   165.617 1.00
      <br/>
      --  55.63
      <br/>
      -- ATOM      2447   CA     CYS    502     38.563  105.427   168.336 1.00
      <br/>
      --  53.33
      <br/>
      -- ATOM      2454   CA     VAL    503     41.155  105.639   171.100 1.00
      <br/>
      --  52.46
      <br/>
      -- ATOM      2462   CA     ARG    504     39.866  106.944   174.425 1.00
      <br/>
      --  51.00
      <br/>
      -- ATOM      2479   CA     THR    505     42.588  106.921   177.117 1.00
      <br/>
      --  50.42
      <br/>
      -- ATOM      2488   CA     PHE    506     41.955  104.935   180.331 1.00
      <br/>
      --  43.64
      <br/>
      -- ATOM      2500   CA     TYR    507     43.306  105.190   183.809 1.00
      <br/>
      --  41.84
      <br/>
      -- ATOM      2514   CA     GLU    508     42.651  101.611   185.218 1.00
      <br/>
      --  39.35
      <br/>
      -- ATOM      2524   CA     THR    509     44.156  99.096    187.597 1.00
      <br/>
      --  41.67
      <br/>
      -- ATOM      2533   CA     PRO    510     46.618  96.563    185.969 1.00
      <br/>
      --  39.70
      <br/>
      -- ATOM      2540   CA     LEU    511     44.134  93.600    186.416 1.00
      <br/>
      --  42.72
      <br/>
      -- ATOM      2549   CA     GLN    512     41.460  95.632    184.624 1.00
      <br/>
      --  37.47
      <br/>
      -- ATOM      2561   CA     LEU    513     43.895  96.148    181.765 1.00
      <br/>
      --  27.02
      <br/>
      -- ATOM      2570   CA     LEU    514     44.769  92.421    181.627 1.00
      <br/>
      --  24.55
      <br/>
      -- ATOM      2579   CA     GLU    515     41.076  91.327    181.688 1.00
      <br/>
      --  31.93
      <br/>
      -- ATOM      2589   CA     LYS    516     40.903  93.442    178.515 1.00
      <br/>
      --  31.96
      <br/>
      -- ATOM      2602   CA     VAL    517     43.981  91.949    176.692 1.00
      <br/>
      --  26.46
      <br/>
      -- ATOM      2610   CA     LYS    518     42.528  88.538    177.852 1.00
      <br/>
      --  30.83
      <br/>
      -- ATOM      2623   CA     ASN    519     39.106  89.397    176.432 1.00
      <br/>
      --  37.62
      <br/>
      -- ATOM      2634   CA     VAL    520     40.221  90.488    172.933 1.00
      <br/>
      --  35.75
      <br/>
      -- ATOM      2642   CA     PHE    521     42.191  87.109    172.662 1.00
      <br/>
      --  25.45
      <br/>
      -- ATOM      2654   CA     ASN    522     39.292  85.079    173.953 1.00
      <br/>
      --  26.73
      <br/>
      -- ATOM      2665   CA     GLU    523     36.870  86.722    171.437 1.00
      <br/>
      --  33.04
      <br/>
      -- ATOM      2675   CA     THR    524     39.260  86.923    168.369 1.00
      <br/>
      --  29.70
      <br/>
      -- ATOM      2684   CA     LYS    525     39.423  83.195    169.011 1.00
      <br/>
      --  28.41
      <br/>
      -- ATOM      2697   CA     ASN    526     35.624  82.663    169.124 1.00
      <br/>
      --  34.46
      <br/>
      -- ATOM      2708   CA     LEU    527     34.816  84.653    166.021 1.00
      <br/>
      --  28.09
      <br/>
      -- ATOM      2717   CA     LEU    528     37.617  82.902    164.068 1.00
      <br/>
      --  25.62
      <br/>
      -- ATOM      2726   CA     ASP    529     35.899  79.662    164.964 1.00
      <br/>
      --  35.00
      <br/>
      -- ATOM      2735   CA     LYS    530     32.659  81.068    163.537 1.00
      <br/>
      --  37.54
      <br/>
      -- ATOM      2748   CA     ASP    531     34.250  82.150    160.272 1.00
      <br/>
      --  37.92
      <br/>
      -- ATOM      2757   CA     TRP    532     38.053  82.453    159.573 1.00
      <br/>
      --  40.02
      <br/>
      -- ATOM      2773   CA     ASN    533     38.395  85.446    157.159 1.00
      <br/>
      --  42.64
      <br/>
      -- ATOM      2784   CA     ILE    534     35.840  87.437    159.393 1.00
      <br/>
      --  39.27
      <br/>
      -- ATOM      2793   CA     PHE    535     38.635  89.996    159.881 1.00
      <br/>
      --  40.49
      <br/>
      -- ATOM      2805   CA     SER    536     38.485  90.720    156.238 1.00
      <br/>
      --  46.56
      <br/>
      -- ATOM      2813   CA     LYS    537     35.844  93.371    157.102 1.00
      <br/>
      --  45.61
      <br/>
      -- ATOM      2826   CA     ASN    538     35.653  96.936    155.760 1.00
      <br/>
      --  54.39
      <br/>
      -- ATOM      2837   CA     CYS    539     35.786  98.626    159.004 1.00
      <br/>
      --  50.55
      <br/>
      -- ATOM      2844   CA     ASN    540     36.738  101.888   157.286 1.00
      <br/>
      --  58.49
      <br/>
      -- ATOM      2855   CA     ALA    541     33.143  102.934   157.648 1.00
      <br/>
      --  61.90
      <br/>
      -- ATOM      2861   CA     SER    542     32.854  101.855   161.326 1.00
      <br/>
      --  56.62
      <br/>
      -- ATOM      2869   CA     PHE    543     35.911  103.888   162.235 1.00
      <br/>
      --  55.25
      <br/>
      -- ATOM      2881   CA     ALA    544     33.885  107.102   161.741 1.00
      <br/>
      --  61.94
      <br/>
      -- ATOM      2887   CA     GLU    545     30.949  107.003   164.203 1.00
      <br/>
      --  63.83
      <br/>
      -- ATOM      2897   CA     CYS    546     33.917  107.418   166.572 1.00
      <br/>
      --  61.90
      <br/>
      -- ATOM      2904   CA     SER    547     33.751  110.878   168.150 1.00
      <br/>
      --  66.22
      <br/>
      -- ATOM      2912   CA     ALA    548     37.461  110.300   168.811 1.00
      <br/>
      --  65.91
      <br/>
      -- END
    </p>
  </description>
  <claims format="original" lang="en" id="claim_en">
    <claim num="1">
      <claim-text>What is claimed is:</claim-text>
      <claim-text>1.</claim-text>
      <claim-text>An isolated, purified, and soluble extracellular domain fragment of a human macrophage colony stimulating factor (M-CSF) receptor comprising the amino acid sequence of SEQ ID NO:11 and wherein said extracellular domain fragment does not comprise a transmembrane region.</claim-text>
    </claim>
    <claim num="2">
      <claim-text>2. An isolated, purified, and soluble extracellular domain fragment of a human macrophage colony stimulating factor (M-CSF) receptor consisting essentially of the amino acid sequence of SEQ ID NO:11 and wherein said extracellular domain fragment does not comprise a transmembrane region.</claim-text>
    </claim>
    <claim num="3">
      <claim-text>3. An isolated, purified, and soluble and dimerizing extracellular domain fragment of a human macrophage colony stimulating factor (M-CSF) receptor, wherein said extracellular domain fragment consists of the amino acid sequence of SEQ ID NO:11.</claim-text>
    </claim>
  </claims>
</questel-patent-document>